Fixing Misallocation with Guidelines: Awareness vs. Adherence

Jason Abaluck
Leila Agha
David Chan
Daniel Singer
Diana Zhu*

October 16, 2020

Abstract

Expert decision-makers often deviate from evidence-based guidelines. If experts lack awareness of guidelines, dissemination may improve outcomes. If experts who are aware of guidelines continue to deviate, promoting stricter adherence has ambiguous effects on outcomes, depending on whether experts use information not encoded in guidelines. We study the role of guidelines in physician decisions to prescribe anticoagulants for atrial fibrillation patients. Anticoagulation reduces stroke risk but increases hemorrhage risk. By text-mining physician notes for guideline mentions, we identify when each physician becomes aware of a new guideline. Once aware of the guideline, physicians pivot their practice patterns to align more closely with the recommendations, but guideline adherence remains far from perfect. To evaluate whether continued non-adherence reflects physicians’ superior information, we combine observational data on treatment choices with new machine learning estimates of heterogeneous treatment effects from eight randomized controlled trials. When physicians depart from guidelines, they are not responding to measurable treatment effect heterogeneity. Improving adherence to the current guideline produces much larger gains than making all physicians aware of the guideline. Adherence to an optimal rule would prevent 47% more strokes without increasing hemorrhages.

*Abaluck: Yale University and NBER, jason.abaluck@yale.edu. Agha: Department of Economics, Dartmouth College, and NBER, leila.agha@dartmouth.edu. Chan: Stanford University, Department of Veterans Affairs, and NBER, david.c.chan@stanford.edu. Singer: Harvard University and Massachusetts General Hospital, desinger@mgh.harvard.edu. Zhu: Yale University, diana.zhu@yale.edu. For helpful comments and suggestions we thank Fiona Scott Morton, Jonathan Gruber, Erzo Luttmer, Jonathan Skinner, Frank Sloan, Doug Staiger, and Mintu Turakhia. We are grateful to Mohit Agrawal, Sophie Andrews, Samuel Areenberg, Liberty Greene, Johnny Huynh, Chris Lim, Uyseok Lee, and Natalie Nguyen for invaluable research assistance. We thank Carl van Walraven and the Atrial Fibrillation Investigators for generously sharing the AFI database for reanalysis.
1 Introduction

In medicine and in many other settings, expert decision-makers often deviate from guideline recommendations (Stevenson and Doleac, 2019; Arrowsmith et al., 2015; Grimshaw and Russell, 1993; Prior et al., 2008). Physicians may deviate because they lack awareness of guidelines; in this case, guideline dissemination may reduce deviations and improve health outcomes as long as guidelines are well-crafted. If physicians are aware of guidelines but continue to deviate, promoting stricter adherence may worsen or improve outcomes, depending on whether physicians have information not encoded in guidelines.

Understanding deviations from guidelines is especially urgent in healthcare, where research documents large inefficiencies in care allocation.¹ Clinical guidelines have been the principal strategy used to encourage evidence-based care, with approximately 250,000 peer-reviewed papers about clinical scoring systems published over the past 50 years (Challener et al., 2019). Efforts to encourage greater guideline adherence have been criticized because they discount the role of physician expertise in tailoring individualized treatments (Costantini et al., 1999; Woolf et al., 1999; Basu et al., 2014). A crucial question in health economics is whether greater guideline awareness or adherence would correct or exacerbate care misallocation.

In this paper, we study how physicians employ an existing clinical guideline and then evaluate their treatment choices using novel machine learning (ML) estimates of treatment effects that incorporate many patient characteristics absent from current guidelines. This approach allows us to test whether physician treatment choices depend on information about treatment effects not encoded in guidelines and to investigate how guideline awareness affects this dependence. We measure the impact on patient outcomes of both guideline “awareness,” the change in behavior when physicians begin to use a guideline, and stricter “adherence”, the degree to which a physician follows guideline recommendations.

We focus on the clinical setting of atrial fibrillation, a common condition afflicting more than 5 million people in the US (Colilla et al., 2013). The principal risk in atrial fibrillation is debilitating or deadly ischemic stroke (hereafter, stroke); untreated patients have a 5% risk of stroke per year (Atrial Fibrillation Investigators, 1995). Anticoagulation (blood thinning) has been shown in clinical trials

¹Abaluck et al. (2016) and Ribers and Ullrich (2019) show that physicians allocate testing inefficiently across patients. Mullainathan and Obermeyer (2019) and Chandra and Staiger (2020) show evidence of misallocation in heart attack testing and treatments. Similar misallocations have been shown in the setting of C-sections (Currie and MacLeod, 2017), depression (Currie and MacLeod, 2020), pneumonia (Chan et al., 2019), and emergency department care (Gowrisankaran et al., 2017).
to reduce stroke risk; however, anticoagulation also increases the risk of life-threatening hemorrhage (hereafter, bleed), including intracranial bleeding (Atrial Fibrillation Investigators, 1995). Therefore, the consequences of misallocating anticoagulation can be serious. In response to these stakes, researchers have developed the CHADS2 score: a simple predictive score of stroke risk for patients with atrial fibrillation (Gage et al., 2001). Clinical guidelines recommend tailoring treatment decisions on the basis of patients’ CHADS2 scores (Members et al., 2006; Hirsh et al., 2008). The CHADS2 score is among the most well known and widely used risk scores used for any clinical condition.

We study guideline awareness and treatment decisions of nearly 5,800 physicians treating 113,000 newly diagnosed atrial fibrillation patients in the Veterans Health Administration (VHA) from 2002-2013. For each physician, we measure the date that the physician first incorporates the CHADS2 guideline into their decision-making, by identifying the earliest mention of the CHADS2 score in the physician’s clinical notes. Following the publication of CHADS2-based treatment guidelines in 2006, we see steady growth in guideline adoption. Prior to adoption, physicians treat roughly 50% of patients with atrial fibrillation, and treatment probability is largely invariant to the CHADS2 score. After the first CHADS2 mention, practice patterns pivot towards CHADS2-based recommendations: prescriptions to patients with low risk scores fall by 4.9 percentage points, while prescriptions to patients with high risk scores increase by 1.6 percentage points. Despite these changes, adopters still fail to adhere to guidelines in more than 40% of cases. Most non-adherence is not explained by a lack of guideline awareness.

To assess the benefits of guideline awareness as well as the possible benefits stricter adherence, we need to understand how treatment effects vary across patients. To this end, we generate novel ML estimates of heterogeneous treatment effects from randomized control trial (RCT) microdata. To estimate heterogeneous treatment effects, we use detailed patient characteristics, clinical outcomes, and randomized treatment status of each patient from eight RCTs in the Atrial Fibrillation Investigators database (hereafter, AFI database) (van Walraven et al., 2009). Using a causal forest model (Wager and Athey, 2017), we obtain treatment effects on strokes and bleeds that vary both with patient characteristics included in the CHADS2 score and with other detailed characteristics. We find that the CHADS2 score explains 25% of the variation in causal forest stroke treatment effects, indicating substantial residual variation.

Researchers affiliated with the Mayo Clinic report that the CHADS2 and its successor the CHA2DS2-VASc were the most common search queries in their internal clinical decision support tool (Challener et al., 2019). MDCalc.com, the popular website for calculating risk scores, currently lists CHA2DS2-VASc as second-highest in popularity and CHADS2 as sixth-highest in popularity.
Exporting the ML-estimated treatment effects to the VHA, we estimate a model of clinician treatment decisions. Our goal is to understand the extent to which treatment deviations from CHADS\textsubscript{2} recommendations may be motivated by residual variation in stroke and bleed treatment effects that are not codified in the guideline. Our first finding is that residual variation in stroke treatment effects (i.e., orthogonal to the CHADS\textsubscript{2} score) explains almost none of the variation in treatment decisions. New awareness of the CHADS\textsubscript{2} score (proxied by first mention of the score in a doctor’s clinical notes) leads doctors to place greater decision weight on CHADS\textsubscript{2}-related variation in stroke treatment effects and, in some specifications, less weight on bleed treatment effects.

These results suggest that departures from guidelines generally worsen patient outcomes. This interpretation relies on two key assumptions. First, our estimates of treatment effects in the AFI data must be externally valid in the VHA data. To assess the external validity of our estimates, we demonstrate that treatment effects estimated on subsets of our trial database predict treatment effects in “out-of-bag” trials not used in estimation, and we show that observables in the VHA data are “in the support” of the variation in the AFI data. This evidence suggests that our estimates likely generalize to the VHA setting, but does not conclusively establish this point. Second, we require that doctors are not making treatment decisions based on variation in treatment effects which cannot be predicted by the covariates in the AFI data. To investigate this, we add to the model detailed patient characteristics that may relate to the benefits of treatment despite not being available in the RCT data; these include variables that predict patient medication adherence, bleed risk, and fall risk. These characteristics explain very little of the variance in treatment choices given estimated treatment effects and do not impact the other coefficients in the model, suggesting that deviations from guidelines are primarily idiosyncratic and not easily reconciled by other considerations raised by the clinical literature.

Under these assumptions, we use the model to simulate the impact of broader adoption or stricter adherence to existing and new guidelines. We consider the frontier of stroke and bleed outcomes which are possible following each decision rule, while varying the fraction of patients treated from 0\% to 100\%. Our findings suggest that physicians allocate treatments to patients with atrial fibrillation only slightly better than a random decision rule. Some of this inefficiency is explained by physicians’ aversion to treating older patients, as the rate of strokes prevented per bleed induced remains roughly constant as patients age, but doctors are much less likely to treat older patients. Extending CHADS\textsubscript{2} adoption (with observed levels of adherence) to non-adopters would modestly improve treatment allocation, preventing an additional 8 strokes per 10,000 patients annually, or a 4\% increase in strokes prevented by warfarin.
The benefits of strict guideline adherence to current guidelines are much larger than the benefits of universal guideline awareness. Reallocating the same number of treatments in the observed allocation to patients with the highest CHADS\textsuperscript{2} scores would prevent 13% more strokes than the status quo for the same number of bleeds. Strict adherence to a guideline which incorporates all information about heterogeneity in stroke treatment effects would prevent 38% more strokes. Reallocating treatments to patients with the greatest ratio of strokes prevented per bleed induced could prevent 47% more strokes without increasing the number of bleeds. These results suggest that policies that aim to increase adherence at the intensive margin may produce much larger improvements in patient outcomes than policies that only broaden adoption at the extensive margin.

Incorporating more variables can improve guidelines, but only if that information is properly weighted. A subsequent refinement to the CHADS\textsuperscript{2} score called the CHA\textsubscript{2}DS\textsubscript{2}-VASc was introduced in 2010, changing the weighting on age and adding vascular disease as a component. While vascular disease does predict stroke treatment effects, the CHA\textsubscript{2}DS\textsubscript{2}-VASc score gave it too much weight and the new score performs worse than the prior version at minimizing strokes per induced bleed. Incorporating more variables that predict strokes does not necessarily improve guidelines if those variables are not weighted in proportion to their impact on treatment effects.

Incorporating more variables can improve guidelines, but only if that information is properly weighted. A subsequent refinement to the CHADS\textsuperscript{2} score called the CHA\textsubscript{2}DS\textsubscript{2}-VASc was introduced in 2010, changing the weighting on age and adding vascular disease as a component. While vascular disease does predict stroke treatment effects, the CHA\textsubscript{2}DS\textsubscript{2}-VASc score gave it too much weight and the new score performs worse than the prior version at minimizing strokes per induced bleed. Incorporating more variables that predict strokes does not necessarily improve guidelines if those variables are not weighted in proportion to their impact on treatment effects.

Our research relates to several strands of literature. First, we contribute to an active literature in economics studying the potential for machine-based algorithms to improve decision-making. Evidence from judge bail decisions (Kleinberg et al., 2018) and clinical care (Abaluck et al., 2016; Mullainathan and Obermeyer, 2019) suggests that human experts make frequent mistakes that could be corrected by optimal guidelines, but do not analyze how guidelines impact behavior in practice. Hoffman et al. (2018) finds that managers hiring low-skilled workers frequently overrule a technology-driven hiring recommendation, but that doing so worsens outcomes. We build on this research by studying highly-skilled experts making an important clinical decision; we analyze how new awareness of a guideline changes behavior and outcomes, in addition to simulating the impacts of stricter adherence to existing and novel guidelines.

In addition, prior papers in this literature comparing machine decisions to human discretion have typically relied on observational data and quasi-experimental assumptions to reach conclusions about misallocation. A recent econometric literature has pointed out that many quasi-experiments that

\footnote{Many of these papers compare treatments and outcomes across decision-makers, usually assuming a common ranking of cases across decision-makers (e.g., Abaluck et al., 2016; Kleinberg et al., 2018; Chandra and Staiger, 2020). Newer approaches in Chan et al. (2019) and Arnold et al. (2020) relax this assumption but restrict the direction of treatment effects. In another vein, recent papers have applied ML techniques to predict outcomes using observational data, again with necessary quasi-experimental assumptions because outcomes are selectively observed (e.g., Ribers and Ullrich, 2019;
recover treatment effects averaged across subgroups of data may nevertheless fail to meet the strict assumptions required for identifying treatment effects within each subgroup of data (e.g., Kolesar et al., 2015; de Chaisemartin, 2017; Frandsen et al., 2019).

Our findings also relate to recent work highlighting challenges that arise when applying evidence from clinical trials to inform treatment decisions more generally. Manski (2017) cautions that we should not privilege the internal validity of trials over external validity in the setting of interest. We address this concern by “clustering” our treatment effect estimates so that the objective is to fit treatment effects in “out-of-bag” trials not used in estimation. We further validate predicted treatment effects in out-of-bag trials with a “best linear predictor” regression, following (Chernozhukov et al., 2018). Einav et al. (2019) and Oster (2020) both report that healthier patients are more likely to take up recommended health screenings and diets. This selection can bias observational estimates and may imply that those treated as a result of guidelines have smaller treatment effects than inframarginal patients. In contrast to these papers, we study guidelines that are primarily targeted at physician treatment decisions, rather than patient-driven health behaviors, and we find no evidence that marginal patients treated due to CHADS$_2$ adoption have smaller (or larger) treatment effects. These differences suggest that the degree of selection on treatment effects may depend on whether physicians or patients are adopting the guideline.

In the medical literature, research has focused on how treatment decisions relate to clinical guidelines. The literature has shown widespread lack of adherence, not only in the case of the CHADS$_2$ score, but also across many clinical risk scores and guidelines. Our paper builds on this literature by documenting that even adopting physicians who are aware of the guideline continue to deviate frequently. The crucial difficulty in interpreting non-adherence is the lack of evidence on whether counterfactual treatment decisions promoted by guidelines will improve health outcomes. For example, Mehta et al. (2015) report that physicians who adhere more closely to guidelines have better outcomes but do not separate the impact of guidelines from other differences across physicians. We address this problem by recovering granular heterogeneous treatment effects with ML techniques and RCT data and applying these treatment effects to assess observed and counterfactual treatment behavior.

The remainder of this paper is organized as follows. Section 2 provides clinical background. 

---

*Mullainathan and Obermeyer, 2019.*

4An older review article estimated that 40% of patients were not receiving guideline-recommended care for chronic conditions (Schuster et al., 1998). More recent research suggests non-adherence to guidelines continues to be widespread across a variety of clinical contexts (Lasser et al., 2016; Valle et al., 2015; Chen et al., 2015; Rosenberg et al., 2015). For the CHADS$_2$ score specifically, Chapman et al. (2017) find evidence of substantial non-adherence to the guideline.
Section 3 describes our data. Section 4 provides reduced form evidence of the impact of CHADS₂ adoption on treatment. Section 5 presents our estimates of causal forest treatment effects. Section 6 models how guideline adoption impacts the relationship between treatment behavior and treatment effects. Section 7 considers counterfactual policies. Section 8 concludes with a discussion of policy implications.

2 Atrial Fibrillation and the CHADS₂ Score

Atrial fibrillation is the most common cardiac arrhythmia. It afflicts over 5 million Americans; for adults older than 40 years, one in four will develop the condition (Hsu et al., 2016). Atrial fibrillation increases stroke risk by five-fold and is responsible for 40% of strokes among patients older than 80 years (Piccini and Fonarow, 2016). The main treatment to reduce stroke risk among patients with atrial fibrillation is anticoagulation by warfarin. While anticoagulation is effective in reducing stroke risk, by 68% on average, it has also been shown to increase the risk of major bleeding by more than twofold (Atrial Fibrillation Investigators, 1995; Kearon et al., 2012). Given the large potential benefits and risks of anticoagulation, an important task for clinicians evaluating patients with atrial fibrillation is to decide which patients to treat with anticoagulation.

Efforts to improve anticoagulation targeting have largely focused on predicting stroke risk, with the intuition that the benefits of anticoagulation are likely increasing in baseline stroke risk. Earlier studies re-analyzed data from the control arms of randomized trials of patients with atrial fibrillation to find hypertension and prior stroke as important risk factors of stroke (Atrial Fibrillation Investigators, 1995; Stroke Prevention in Atrial Fibrillation Investigators, 1995). Building on this work, the CHADS₂ score was first formulated by Gage et al. (2001), using registry data comprising 1733 Medicare patients, and later validated for clinical practice by Gage et al. (2004). In 2006, the American College of Cardiology (ACC) became the first specialty society to issue a guideline recommending treatment decisions based on the CHADS₂ score (Members et al., 2006). Other professional societies followed, with the American College of Chest Physicians (ACCP) recommending CHADS₂-based treatment decisions in 2008 (Hirsh et al., 2008).

Designed to be easy to use, the CHADS₂ score is an index of five patient characteristics: “C” for

---

5In our sample, fewer than 2% of patients are prescribed alternative anticoagulants. Novel oral anticoagulants (NOACs) were introduced near the end of our sample, with the FDA approval of dabigatran in 2010, rivaroxaban in 2011, and apixaban in 2012. Based on non-inferiority trials, they are similarly effective in preventing stroke with possibly lower risks of bleeding (Lane and Lip, 2012). Guideline recommendations for their use (vs. no anticoagulation) rely on the same stroke risk scores. Warfarin continues to be the mainstay drug for anticoagulation in atrial fibrillation (Hsu et al., 2016).
congestive heart failure (1 point), “H” for hypertension (1 point), “A” for age ≥ 75 years (1 point), “D” for diabetes (1 point), and “S” for stroke (2 points) (Table 1). Since its introduction, the CHADS\textsubscript{2} score has become one of the most widely recognized risk scores in clinical practice.\textsuperscript{6} However, despite its widespread recognition, studies in a variety of settings have shown that adherence to the CHADS\textsubscript{2} score has been low, typically with only half of recommended patients being prescribed anticoagulation (Hsu et al., 2016; Piccini and Fonarow, 2016).

While poor adherence to CHADS\textsubscript{2}-based treatment recommendations has been linked to many factors, physicians’ concerns of increased bleeding risk due to frailty and multi-morbidity are commonly cited. Frailty and multi-morbidity often coexist with atrial fibrillation, since both conditions increase in prevalence with age. Less evidence has existed to guide physicians to assess bleeding risk. The first formal risk score for bleeding (HAS-BLED) was published toward the end of our study period (Lane and Lip, 2012). However, it remains unvalidated in the population of atrial fibrillation patients and is not as widely used in clinical practice. Therefore, while guidelines have discussed the need to consider bleeding risk, they do not offer rules that formally consider both stroke and bleeding risk (let alone treatment effects). In recent years, more evidence has emerged to support the use of anticoagulation in frail and multi-morbid patients; nevertheless, the uptake of anticoagulation among patients who are frail and have a high-risk of stroke remains low (Fawzy et al., 2019).

3 Data

Our approach combines data from two main sources. We study treatment decisions in the context of guideline adoption using data from the Veterans Health Administration (VHA). We estimate heterogeneous treatment effects using RCT data from the Atrial Fibrillation Investigators (AFI) database.

3.1 Veterans Health Administration Cohort

To study initial treatment decisions, we identify patients with a new diagnosis of atrial fibrillation using electronic medical records from the Veterans Health Administration (VHA) from October 2002 to December 2013. Following a protocol in previous work, we err on the side of defining a narrower

---

\textsuperscript{6}In 2010, a modification of the CHADS\textsubscript{2} score, the CHA\textsubscript{2}DS\textsubscript{2}-VASc score, was introduced (Lip et al., 2010). The CHA\textsubscript{2}DS\textsubscript{2}-VASc score changes the weighting of age and introduces vascular disease as an additional risk factor. Due to the time period covered by our data, from 2003-2013, our analysis focuses principally on the original CHADS\textsubscript{2} score. We observe comparatively little use of the CHA\textsubscript{2}DS\textsubscript{2}-VASc score: while 23% of patient encounters in our data are by physicians who have previously mentioned the CHADS\textsubscript{2} score, fewer than 2% of patient encounters are by physicians who have previously mentioned the CHA\textsubscript{2}DS\textsubscript{2}-VASc in their notes. We do consider vascular disease in our causal forest model of treatment effects, and in some simulations, we contrast the CHADS\textsubscript{2} and CHA\textsubscript{2}DS\textsubscript{2}-VASc scores.
cohort of patients who are more likely both to have a new, confirmed atrial fibrillation diagnosis and to receive care at the VHA (Turakhia et al., 2013; Perino et al., 2017).

We first identify potentially new diagnoses of atrial fibrillation (ICD9 code beginning with 427.3) among patients with no previous such diagnosis within three years, extending our data back to October 1999 to perform this exclusion. We also require an electrocardiogram (the primary means to diagnose atrial fibrillation) near the time of initial diagnosis and no anticoagulation prior to the initial diagnosis. After a diagnosis of atrial fibrillation, the anticoagulation decision is typically made by a physician who provides longitudinal care and makes prescription decisions for the patient. Therefore, to attribute patients to physicians who are likely responsible for anticoagulation decisions, we require each patient to have a visit with a VHA cardiologist or primary care physician (PCP) within 90 days after the initial diagnosis (to decide on treatment). Further, the patient must have received at least one drug (other than warfarin) prescribed by the attributed physician within one year before or after the atrial fibrillation diagnosis. We also require each attributed physician to have at least 30 other patients with atrial fibrillation and to have prescribed warfarin for another patient. Our sample restrictions result in an analytic cohort of 113,270 patients (see Table 2 for details).

For each patient in this cohort, we capture a broad array of characteristics that may influence the anticoagulation decision following an initial diagnosis. These characteristics include demographic information, comorbidities, laboratory test results, body measurements, and blood pressure readings. We use these characteristics to construct the CHADS\textsubscript{2} score, match the other clinical characteristics recorded in the RCT data, and to proxy for other concerns not fully captured in the RCT data (e.g., bleed risk, fall risk, frailty, multi-morbidity). To capture the anticoagulation decision, we rely on VHA records of prescriptions for warfarin or a newer oral anticoagulants (e.g., dabigatran, rivaroxaban, apixaban, edoxaban).

Finally, we measure adoption of the CHADS\textsubscript{2} score at the physician level by searching physician visit notes for mention of the CHADS\textsubscript{2} score. We consider physicians who have mentioned

\footnote{For further details on the additional patient comorbidities and risk factors we extracted from the VHA sample, see Appendix Section A.4.}

\footnote{The VHA records include prescriptions that are dispensed by the VHA as well as prescriptions that are paid for by the VHA. Recall that the vast majority of prescriptions in our sample are for warfarin. Fewer than 2\% of patients in our sample are prescribed a novel oral anticoagulant (NOAC). Among patients prescribed an anticoagulant, 4\% are prescribed a NOAC.}

\footnote{Recall that physicians in our analytic sample are cardiologists and PCPs who have each treated at least 30 atrial fibrillation patients. We increase our detection of CHADS\textsubscript{2} mentions for these physicians by using visit notes within 6 months of initial diagnosis in our broad cohort of 844,312 atrial fibrillation patients, who may be patients with previously established diagnoses (see Table 2), and search for non-case-sensitive occurrences of the string chads. We settled on this string after spot-checking several variants for false positives. Consistent with our spot-checking results, we find no positive mentions of this string in the first two years of our data, prior to diffusion of the CHADS\textsubscript{2} score. This suggests that false positives are rare for this token in our data.}
the CHADS$_2$ score in a note as “adopters” of the CHADS$_2$ score guideline, in the sense that they recognize the CHADS$_2$ score and have used it in their decision-making. We proxy a physician’s time of CHADS$_2$ adoption by the physician’s first note mentioning the CHADS$_2$ score. We categorize physicians without any note mentioning the CHADS$_2$ score as non-adopters.

Table 3 reports summary statistics for adopters and non-adopters. Overall, 50% of patients in our sample receive anticoagulation. Patient characteristics are similar for adopters and non-adopters. While roughly half of the physicians in our sample are adopters, adopters tend to have more patients in our sample than do non-adopters. Patients seen by adopters and non-adopters are similar in age and have similar prevalence rates of CHADS$_2$ risk factors.

### 3.2 Atrial Fibrillation Investigators Database

To estimate heterogeneous treatment effects—which we use to assess physician decision-making and to evaluate counterfactual anticoagulation decisions on patient outcomes—we rely on the Atrial Fibrillation Investigators database (hereafter, AFI database). The AFI database contains patient-level observations from eight trials in which patients were randomized to anticoagulants versus a placebo or control. Details of the AFI database have been documented elsewhere (e.g., van Walraven et al., 2009).

The AFI database was previously compiled by investigators to explore heterogeneity in risk and in treatment effects. Previous analyses using the database have selected patient characteristics heuristically (van Walraven et al., 2002, 2009). For each patient in the AFI database, we observe randomization status and subsequent stroke and bleeding events. In harmonizing data across the clinical trials, the investigators consistently recorded several important patient characteristics at the time of randomization, including all variables underlying the CHADS$_2$ score, as well as several additional variables, including further detail on demographics, height, weight, blood pressure, hemoglobin, smoking status, comorbidities, and history of transient ischemic attack (TIA), stroke, anginal symptoms, and myocardial infarction. In Appendix Table A.1, we list the full set of characteristics that we use from the AFI database. In Appendix Table A.3, we report the results of balance tests, which suggest successful randomization in these clinical trials.

---

Notes:
- There are a total of ten trials in the original AFI database. For our analysis, we define patients who were treated with aspirin alone as being untreated with anticoagulation. We drop observations for patients on low warfarin or low warfarin plus aspirin therapy. After these modifications, eight trials remain with both treatment and control arms. In two of the eight trials, patients are divided into eligible versus ineligible groups for anticoagulation and then randomized among eligible patients. We treat the ineligible patients as separate trials (with only one treatment arm) and use data from all trials in the causal forest implementation to increase power.
4 CHADS<sub>2</sub> Guideline Adoption and Adherence

The 2006 ACC and 2008 ACCP guidelines recommended treating patients with a CHADS<sub>2</sub> score of 0 or 1 potentially with aspirin alone and treating patients with a CHADS<sub>2</sub> score of 2 or above with anticoagulation (Hirsh et al., 2008; Members et al., 2006). We therefore begin our analysis by describing trends in prescribing behavior for groups of patients defined by their CHADS<sub>2</sub> score.

Figure 1 displays trends in anticoagulation rates for patients with low risk of stroke (CHADS<sub>2</sub> score of 0 or 1), patients with moderate risk of stroke (CHADS<sub>2</sub> score of 2 or 3), and patients with high risk of stroke (CHADS<sub>2</sub> score of 4 or greater). Prior to the 2006 guideline, patients with lower CHADS<sub>2</sub> scores were remarkably more likely to be treated with anticoagulation. This relationship held both between patients with low vs. moderate stroke risk and between patients with moderate vs. high stroke risk. In the years after 2006, we observe a gradual reduction in anticoagulation rates for low-risk patients for whom the guideline allowed for management without anticoagulation. There appears to be a small increase in treatment rates for patients at moderate or high risk. However, even among groups where anticoagulation is recommended, prescription rates remain below 55% for our sample period. Patients with high stroke risk (CHADS<sub>2</sub> score of 4 or greater) remain slightly less likely to be treated than patients with moderate stroke risk (CHADS<sub>2</sub> of 2 or 3).

It is evident from Figure 1 that physicians had only weak adherence to recommendations to treat patients with high CHADS<sub>2</sub> risk scores and to leave patients with low CHADS<sub>2</sub> risk scores untreated. We next examine when physicians mention the CHADS<sub>2</sub> score in their clinical notes. We interpret these mentions of the risk score as a measure of adoption on the extensive margin, in the sense that physicians recognized the score as a tool to assist in the evaluation of stroke risk and the anticoagulation decision. In Figure 2, we show that almost no physician mentioned the CHADS<sub>2</sub> score in the period prior to the ACC guideline in 2006, despite the fact that the CHADS<sub>2</sub> score was introduced in 2001 and validated in 2004. Following 2006, we find a steady rise in the proportion of physicians who have previously mentioned the CHADS<sub>2</sub> score at least once, approaching 70% near the end of our study period in 2013. We note that this represents a lower bound to awareness of the CHADS<sub>2</sub> score, as physicians may be aware of the score yet not mention it in their notes.

We proceed by estimating the causal impact of guideline adoption on prescription choice and investigating how guideline adherence changes after a physician incorporates the guideline into her

---

<sup>11</sup>In the 2006 and 2008 guidelines, patients with a CHADS<sub>2</sub> score of 0 were recommended aspirin, while patients with a CHADS<sub>2</sub> score of 1 could be treated with either aspirin or anticoagulation. Later guidelines suggested anticoagulation for patients with a CHADS<sub>2</sub> score of 1 and some patients with a CHADS<sub>2</sub> score of 0 but a CHA<sub>2</sub>DS<sub>2</sub>-VA<sub>Sc</sub> score of 1 (Lip et al., 2010). This clinical consensus applied mostly to after our study period.
clinical practice. In the Panel A of Figure 3, we first plot how anticoagulation rates among high- and low-score patients change following an adopting physician’s first note mentioning the CHADS\textsubscript{2} score. Following the adoption event, the anticoagulation rate for low-scoring patients drops by several percentage points, while the anticoagulation rate for higher-scoring patients increases slightly.

We further assess the effect of adoption on adherence by an event-study regression separately for the two guideline-relevant groups of patients:

\begin{equation}
W_i = \sum_{r=-5}^{5} 1(r(i) = r) \theta_r + \eta_{d(i)} + \xi_{t(i)} + \epsilon_i.
\end{equation}

$W_i \in \{0, 1\}$ indicates whether patient $i$ was anticoagulated, and $r(i)$ is a function that returns the year of $i$’s visit relative to the prescribing physician’s date of adoption. The regression includes fixed effects for the prescribing physician, $d(i)$, and for the year, $t(i)$. We estimate Equation (1) separately for patients with CHADS\textsubscript{2} scores of 0 and 1 and for those with CHADS\textsubscript{2} scores 2 and higher. Panel B of Figure 3 displays estimation results of the $\theta_r$ coefficients and is broadly consistent with the raw treatment rates shown in Panel A. Treatment rates for low-score patients decline by 4.7 percentage points on average (standard error of 1.6 percentage points), while higher-score patients experience a small 1.7-percentage-point increase (standard error of 1.1 percentage points).\textsuperscript{12}

Taken together, these results suggest that although the CHADS\textsubscript{2} score was becoming widely adopted, adherence to anticoagulation recommendations increased only modestly with adoption. Prior to the 2006 guideline, almost no physician appeared to be using the CHADS\textsubscript{2} score in documented clinical decision-making, yet by the end of 2013, the vast majority had explicitly mentioned it in their notes. While our event-study results suggest a clear behavioral shift in prescribing at the time of adoption, most of this response is from avoiding treatment for low-risk patients, not increasing treatment for high-risk patients. In Figure A.1, we further show that, while adherence varied substantively across physicians, few physicians reached an adherence rate of 80%.

Adoption is more difficult to measure than adherence. However, two features of our setting lend greater confidence to our results on the effect of adoption and allow us to understand patterns of adherence in the context of adoption. First, the lack of pre-trends in our event-study results in Figure 3 and the timing of the effect suggest that our measure based on clinical documentation coincides with a discrete adoption event. Second, we witness a dramatic shift in the pace of adoption—from nearly no mentions of the CHADS\textsubscript{2} score prior to the ACCP guideline publication, growing to 70% of

\textsuperscript{12} This estimate of changes in treatment rates comes from aggregating the results shown in Figure 3. Specifically, we calculate the difference between the average level in years 0 through 4 minus the average level in years −5 through −1.
doctors having mentioned the score by the end of our study. Falsely classifying physicians who have adopted the guideline but have not mentioned the CHADS\textsubscript{2} score is thus less of a concern, and we can reconcile our event-study results with the overall shifts in adherence among all physicians evident in Figure 1.

These findings are consistent with a clinical literature that emphasizes the importance of reducing stroke risk by anticoagulation and that documents widespread awareness of the CHADS\textsubscript{2} score among physicians, more than a decade after the 2006 ACC guideline (Ashburner et al., 2018; Amroze et al., 2019). Yet in numerous settings, only about half of patients with the highest stroke risks are treated with anticoagulation (Hsu et al., 2016). Our results further show that there is low adherence even among physicians who discuss the CHADS\textsubscript{2} score in their decision-making. Survey evidence suggests that physicians remain hesitant to anticoagulate patients who are elderly, frail, and multi-morbid, out of concern that anticoagulation may result in severe bleeding for these patients (Fawzy et al., 2019). We find descriptive evidence to support this reason behind nonadherence: Appendix Figure A.2 shows that treatment rates actually decline with age after 75 years, despite age being a strong predictor of stroke risk.

5 The Effects of Anticoagulation

The results in the previous section show a gap between extensive-margin CHADS\textsubscript{2} guideline adoption and full adherence to the CHADS\textsubscript{2}-based recommendations. Our interpretation of this gap, as well as policy recommendations for incorporating evidence from clinical trials into practice, will depend on the relative value of physician discretion versus guideline adherence for patient health outcomes.

In the case of atrial fibrillation, physicians may depart from CHADS\textsubscript{2}-based recommendations for good reasons. First, the CHADS\textsubscript{2} score predicts stroke risk, while treatment decisions should be based on stroke treatment effects. Second, the decision to anticoagulate must weigh the reduction of stroke risk against the inducement of bleed risk. The CHADS\textsubscript{2} score is silent on the latter; while risk scores for bleeding have subsequently been developed (Pisters et al., 2010), their adoption has been much lower than the CHADS\textsubscript{2} score. Third, clinicians have access to more patient information than has been encoded in simple risk scores. Tailoring their treatment decisions to this additional information could lead to departures from CHADS\textsubscript{2}-based guidelines.
5.1 Setup and Design

To evaluate treatment decisions and departures from guidelines, we need to characterize counterfactual patient stroke and bleeding outcomes. Let \( Y^s_i (w) \in \{0, 1\} \) denote whether patient \( i \) will have a stroke within one year, depending on anticoagulation \( w \in \{0, 1\} \), and let \( Y^b_i (w) \in \{0, 1\} \) denote a similar object for bleeding within one year. We then define conditional average treatment effects (CATEs) that are a function of patient characteristics, both those that are included in the CHADS\(_2\) score and others that are omitted from it. Specifically, for one-year stroke and bleeding, respectively,

\[
\tau^s (x) = E \left[ Y^s_i (1) - Y^s_i (0) \middle| X_i = x \right];
\]

\[
\tau^b (x) = E \left[ Y^b_i (1) - Y^b_i (0) \middle| X_i = x \right],
\]

where \( X_i \) is a set characteristics belonging to patient \( i \).

We set about estimating these objects by applying “causal forest” ML techniques, as described in Wager and Athey (2017), to RCT-generated data in the AFI database (van Walraven et al., 2002). While many applications of machine learning methods use very large data sets, new work on causal forests apply related methods to estimate CATEs in sample sizes more typical of RCTs in medicine and social science; similar scale RCT applications of causal forest estimation have been previously demonstrated in Athey and Wager (2019); Chernozhukov et al. (2018). We adapt the insights from these analyses to our setting.

The experimental design of RCTs is well-suited for estimating treatment effect heterogeneity, in contrast to many quasi-experimental designs commonly used in the economics literature. First, random assignment of treatment within each cell of patient characteristics \( x \), a crucial requirement to estimate CATEs, is more plausible in RCTs. Second, many quasi-experiments involve monotonicity and exclusion-restriction violations within cells of the data, even if these violations “average out” in the entire sample (e.g., Kolesar et al., 2015; Frandsen et al., 2019). Third, RCTs carefully collect information on infrequent yet important outcomes (e.g., stroke and bleeding) for the disease and treatment being studied. Capturing these events, particularly their timing relative to initiation of treatment, may be challenging in observational data.

5.2 Causal Forest Implementation

We use the algorithm developed in Athey and Wager (2019) for estimating causal forests with conditional random assignment, supplemented by a LASSO variable selection step. We find that the latter
improves performance, especially for bleeds (the rarer of the two outcomes in our data). The LASSO with a cross-validated penalty parameter selects the variables shown in Appendix Table A.2 (column 2 for stroke and column 4 for bleed) from the full set of variables in Appendix Table A.1 (as well as the CHADS\textsuperscript{2} score itself, which is a function of these variables). For bleeds, this procedure leaves just two variables which strongly predict bleed risk: age and race. For strokes, 10 variables are selected. For the remainder of the algorithm, we proceed with the LASSO-selected variables.

We then use regression forests to adjust outcomes and treatment status with expectations based on patient characteristics \( G \) and the RCT trial identifier \( 9 \):

\[
 Y^o(x; j) = E[Y_i^o(0)|X_i = x, j(i) = j], \; o \in \{s, b\}; \quad (4)
\]

\[
 W(x; j) = E[W_i|X_i = x, j(i) = j] \quad (5)
\]

where \( j(i) \) indicates the RCT trial for individual \( i \), and where \( Y^o(x; j) \) is formed using observations in the control arm of each trial. We compute “out-of-bag” estimates \( \tilde{Y}_{-i}^o(x; j) \) and \( \tilde{W}_{-i}(x; j) \) from data excluding \( i \). In our causal forest estimation, we use re-centered outcome and treatment variables: 

\[
 \tilde{Y}_i^a = Y_i - \tilde{Y}_{-i}^o(X_i; j(i)) \; \text{and} \; \tilde{W}_i = W_i - \tilde{W}_{-i}(X_i; j(i)).
\]

The causal forest generates predictions of stroke and bleeding CATEs, \( \tau^s(x) \) and \( \tau^b(x) \) respectively, capturing heterogeneity in treatment effects along patient characteristics observable in the AFI database.\textsuperscript{13} In addition to the variables selected by the LASSO, we include the associated risk score for each outcome, \( \tilde{Y}_{i}^o(X_i; j(i)) \), in the causal forest.

To improve the prediction of treatment effects out of sample (i.e., in the VHA data), we use trial identifiers in the AFI database to implement a “cluster-robust” causal forest with clusters at the trial level (Athey and Wager, 2019). This means that predictions are trained in other trials and then assessed “out-of-bag” on observations in a leave-out trial. This procedure constructs estimates which are externally valid across trials within the AFI database.\textsuperscript{14}

To provide insight into sources of treatment effect heterogeneity, we summarize the “variable importance” of patient characteristics in predicting treatment effect heterogeneity.\textsuperscript{15}

\textsuperscript{13}We estimate treatment effects as a function of \( x \), exclusive of trial indicators, since we will be applying our predictions to an external sample (i.e., the VHA data). The ‘centering’ procedure described in the text is formally justified in Section 6.1.1 of Athey et al. (2019).

\textsuperscript{14}We cross-validate all parameters in the causal forest except for sample fraction and minimum node size. The sample fraction can get too low for estimation to proceed properly when being tuned. Therefore we set the sample fraction to its default value 0.5. We set the minimum node size to 100 to avoid overfitting that occurs at node sizes that are too small. When selected via cross-validation, the causal forest prefers full-grown trees with arbitrarily small node sizes but this specification leads treatment effects to vary implausibly with small changes in continuous variables such as age. These irregularities disappear at a minimum node size of 100.

\textsuperscript{15}There are several methods to compute variable importance, and there is no clear consensus yet on the best method (Wei et al., 2015). We use a measure from Athey et al. (2019) which ranks variables more highly in importance if the algorithm
lists variables ranked by importance in the stroke and bleed causal forests, as well as regression forests estimated to predict risk in the control groups. We also report the sign of each variable in a linear regression of treatment effects on all included variables. The single most important predictor of treatment effects in both the stroke and bleed models is the corresponding regression-forest model of risk. The variables in the CHADS\textsuperscript{2} score generally rank highly in both the causal forest and regression forest models, but several variables not in the CHADS\textsuperscript{2} score also matter: e.g. lower hemoglobin and history of angina or myocardial infarction predict larger stroke treatment effects.

5.3 Validation and Best Linear Predictors

In this section, we validate the estimated heterogeneity to assess concerns about potential over-fitting both within and across trials. Following Athey and Wager (2019), we project outcomes onto leave-out-trial CATE predictions of treatment effects. This exercise also allows us to construct a “best linear predictor” (BLP) of treatment effects given the causal forest estimates (Chernozhukov et al., 2018).\textsuperscript{16} Specifically, for observations in each trial in the AFI database, we make out-of-bag CATE predictions from causal forests grown exclusively from data in the other trials. Denote these leave-out-trial CATE predictions for stroke and bleeding as \( \hat{g}_{-j(i)}^o (x) \), \( o \in \{s, b\} \), for individual \( i \) in trial \( j(i) \) with characteristics \( X_i = x \) (we hereafter suppress the \( i \) in \( j(i) \) to simplify notation). Using regression forests, we also construct and potentially control for predictions of \( \hat{Y}_{-j,1}^o (x) \), using only control group data, and \( \hat{Y}_{-j,2}^o (x) \), using all data but not conditioning on treatment status.

We assess external validity across trials by a regression of realized outcomes \( Y_i^o \) on out-of-bag predictions and trial fixed effects \( \zeta_i \).\textsuperscript{17}

\[
Y_i^o = \left( \delta_0^o + \delta_1^o \hat{g}_{-j}^o (X_i) \right) W_i + \gamma_1^o \hat{Y}_{-j,1}^o (X_i) + \gamma_2^o \hat{Y}_{-j,2}^o (X_i) + \epsilon_i + \zeta_i. \quad (6)
\]

The coefficient \( \delta_1^o \) quantifies the predictive power of heterogeneous CATEs that are estimated in other trials; a coefficient value of \( \delta_1^o = 1 \) would suggest that the causal forest estimates are well calibrated.

\textsuperscript{16}The regression is an OLS version of the BLP procedure. Chernozhukov et al. (2018) suggest a GLS version that has more power in the general case when treatment probabilities vary across trials.

\textsuperscript{17}We include trial fixed effects to address a mechanical negative relationship between CATEs across trials when trials are few. To see this, consider the following decomposition: \( \tau^o(x|j) = \pi^o_j + \tau^o_{x,j} \), where \( \tau^o_{x,j} \) is by construction uncorrelated with \( \pi^o_j \) and \( \pi^o_x \). The heterogeneity of interest in the out-of-bag CATEs, \( \hat{\tau}_{-j(i)}^o (x) \), is driven by variation in \( \pi^o_j \). If there are relatively few trials, then variation in \( \pi^o_j \) will bias downward the relationship between outcomes and CATEs, due to the small-sample negative correlation between \( \hat{\tau}_{-j(i)}^o (x) \) and \( \hat{\tau}^o(x|j) \).
and outcomes for a patient with characteristics \( x \) would increase one-for-one with treatment and the relevant \( \hat{\tau}_j^o(x) \). Using Equation (6), we can further construct, for later use, BLP-based adjustments to the CATEs estimated in Section 5.2:

\[
\hat{\tau}_{BLP}^o(x) = \hat{\delta}_0^o + \hat{\delta}_1^o \hat{\tau}^o(x).
\]

We will use this adjustment directly for CATEs on bleeding.

For strokes, we consider the exact analog of this regression as well as a modified procedure where we decompose treatment effects into two dimensions: stroke treatment effects that vary with the CHADS\(_2\) score, and stroke treatment effects that are orthogonal to the CHADS\(_2\) score. Specifically, we first use a regression to project leave-out-trial stroke CATEs, \( \hat{\tau}_{-j}^s(x) \), onto indicators of the CHADS\(_2\) score. We call the CHADS\(_2\)-projected component \( \hat{\tau}_{-j}^{s(c)}(x) \) and the residual component \( \hat{\tau}_{-j}^{s(r)}(x) \), noting that \( \hat{\tau}_{-j}^s(x) = \hat{\tau}_{-j}^{s(c)}(x) + \hat{\tau}_{-j}^{s(r)}(x) \). We next perform the following BLP projection:

\[
Y^s_i = \left( \hat{\delta}_0^s + \hat{\delta}_1^s \hat{\tau}_{-j}^{s(c)}(X_i) + \hat{\delta}_1^s \hat{\tau}_{-j}^{s(r)}(X_i) \right) W_i + \\
n_1^s \hat{\gamma}^o_1 \hat{\tau}_{-j,1}^o(X_i) + \gamma_2^o \hat{\tau}_{-j,2}^o(X_i) + \xi_j + \epsilon_i.
\]

Using equation (8), we construct BLP-based adjustments to the stroke CATEs as follows:

\[
\hat{\tau}_{BLP}^s(x) = \hat{\delta}_0^s + \hat{\delta}_1^s \hat{\tau}^{s(c)}(x) + \hat{\delta}_1^s \hat{\tau}^{s(r)}(x).
\]

The BLP estimation validates the performance of our causal forest procedure on held-out trials. Results of the BLP procedure are reported in Appendix Table A.4. All of our BLP coefficients on the recovered causal forest treatment effects are significantly different from 0, and we cannot reject the null that each coefficient equals 1. For stroke CATEs, we estimate \( \hat{\delta}_1^s = 1.027 \) (standard error of 0.242). For bleed CATEs, we estimate \( \hat{\delta}_1^b = 1.149 \) (standard error of 0.324). For the CHADS\(_2\) component, we estimate \( \hat{\delta}_1^{s(c)} = 0.763 \) (standard error of 0.340); for the residual component, we estimate \( \hat{\delta}_1^{s(r)} = 1.302 \) (standard error of 0.348). In other words, both components predict treatment effect variation in held-out trials, although the evidence is even stronger for the residual component.

In our subsequent analyses, we will adjust CATEs predicted in Section 5.2 for stroke and bleeding by using Equation (9) for \( \hat{\tau}_{BLP}^s \) and Equation (7) for \( \hat{\tau}_{BLP}^b \). In Appendix Table A.9, we replicate our main results using unadjusted \( \hat{\tau}^s \) and \( \hat{\tau}^b \) as robustness checks and nothing changes qualitatively.
5.4 External Validity in the VHA Data

While clustering at the trial level should yield predictions that are externally valid across trials within the AFI database, we ultimately seek to use treatment effects estimated in the AFI database to evaluate counterfactuals in the VHA data. In order to assess the external validity of CATEs in the VHA data, we compare observable attributes of patients in the AFI database to those in the VHA data to assess whether, at least with respect to observable characteristics, the VHA data lies roughly within the support of the AFI trials.

Table 3 compares the VHA data with the AFI database on some key patient characteristics. The clearest difference in average patient characteristics is in the share of male patients. We estimate CATEs for both male and female patients from the AFI database, allowing the causal forest to use gender to predict treatment effect heterogeneity. Our analysis of variable importance, shown in Appendix Table A.2, finds that patient gender is unimportant in predicting CATEs. Among other patient characteristics, the AFI database has a larger share of the population over 65, a lower incidence of hypertension and diabetes, and a higher rate of congestive heart failure than the VHA data on average. However, in Appendix Table A.5, we can see that for all patient characteristics (including gender), the VHA data mean is within the range of trial means. This mitigates concerns that the types of patients seen in the VHA are not represented in the AFI database.

5.5 Treatment Effect Predictions for VHA Patients

We take causal forest prediction rules trained and validated in the AFI database, in the form of causal forest splits and leaf values, and apply these rules to patients in the VHA data. For the remainder of the paper, we use BLP-adjusted CATEs, with weights defined by our validation exercise in Section 5.3, Equations (7) and (9). Figure 4 shows variability in the distribution of estimated stroke and bleed (BLP-adjusted) CATEs. The 10th percentile stroke treatment effect (corresponding to the largest reductions in stroke risk) is \(-0.083\), while the 90th percentile is \(-0.017\). The impact of warfarin on bleeds is smaller but still variable, ranging from 0.010 at the 10th percentile (smallest increases in bled risk) to 0.038 at the 90th percentile.

We next assess the importance of characteristics omitted from the CHADS\(_2\) score in predicting treatment effects in the VHA population. While stroke treatment effects and the CHADS\(_2\) score are highly correlated, we find substantial residual variation in stroke treatment effects after conditioning on the CHADS\(_2\) score. The \(R^2\) from regressing BLP-adjusted stroke treatment effects, \(\hat{\tau}_{BLP}^s\) on
CHADS\textsubscript{2} score indicators is 0.25. Figure 5 shows that stroke treatment effects increase monotonically with the CHADS\textsubscript{2} score, but that wide variation also exists in the residual component of stroke treatment effects. While patients with higher CHADS\textsubscript{2} scores also have larger anticoagulation inducements in bleeds, there also is variation in bleed treatment effects within each CHADS\textsubscript{2} score. This suggests scope for using more detailed stroke and bleed CATEs in treatment decisions, which we will evaluate in the next section.

6 Assessing Physician Decisions in the VHA

With ML predictions of treatment effects in hand, we turn to assess how physician treatment decisions in the VHA relate to treatment effects. We introduce a model to characterize how treatment decisions respond to treatment effect variation, separately considering variation that is and is not captured by guidelines. This model allows us consider the relative impact of adoption and adherence on patient outcomes. In particular, we will evaluate whether guidelines may lead physicians to neglect information relevant for health outcomes but not incorporated into a guideline. Finally, we use the model to simulate the counterfactual impact of adopting guidelines that incorporate more information about how treatment effects vary across patients.

6.1 Stylized Model of Treatment Decisions

We model how treatment decisions depend on variation in treatment effects as well as the physician’s guideline adoption status. Guideline adoption status is denoted \( g \in \{\text{never, pre, post}\} \), corresponding to decisions made by physicians who never adopt the CHADS\textsubscript{2} score, decisions made by physicians before adopting the CHADS\textsubscript{2} score, and decisions made by physicians after adopting the CHADS\textsubscript{2} score. Anticoagulation decisions \( W_i \) in state \( g \) are made as follows:

\[
W_i = 1\{\beta^s \tilde{\tau}^s_{i,g} + \beta^b \tilde{\tau}^b_{i,g} + f(X_i) + v_i > 0\}. \tag{10}
\]

This model includes two components. First, physicians consider Bayesian posterior beliefs of patient-specific stroke and bleeding treatment effects, \( \tilde{\tau}^s_{i,g} \) and \( \tilde{\tau}^b_{i,g} \), with respective preference weights \( \beta^s \) and \( \beta^b \). Guideline adoption may improve physicians’ information about treatment effects, giving them more accurate posterior beliefs. The second component consists of other factors—including both observable characteristics (to the econometrician) \( f(X_i) \) and otherwise unobservable factors \( v_i \)—
which impact treatment decisions.

In Appendix A.1, we specify a Bayesian model in which posterior beliefs about treatment effects result from a prior and noisy signals. The model implies that posterior beliefs are a linear function of true treatment effects and prior beliefs:

\[
\tilde{\tau}_{i,g}^s = \lambda_g^{s(e)} \tau_i^{s(e)} + \lambda_g^{s(r)} \tau_i^{s(r)} + \mu_g^s + \nu_{i,g}^s; \tag{11}
\]

\[
\tilde{\tau}_{i,g}^b = \lambda_g^{b} \tau_i^{b} + \mu_g^b + \nu_{i,g}^b. \tag{12}
\]

In the equations above, \(\mu_g^s\) and \(\mu_g^b\) are constants within \(g\) (which depend on physician’s priors), and \(\nu_{i,g}^s\) and \(\nu_{i,g}^b\) are noise terms with variances that depend on the precision of the signals that physicians receive. True stroke treatment effects, \(\tau_i^s\), are decomposed into a CHADS\(_2\)-related component \(\tau_i^{s(c)}\) and a residual component \(\tau_i^{s(r)}\), such that \(\tau_i^s = \tau_i^{s(c)} + \tau_i^{s(r)}\). \(\tau_i^b\) is the true treatment effect for bleeding. The parameters \(\lambda^s, \bar{\sigma} \in \{s(e), s(r), b\}\), correspond to the signal-to-noise ratio of posterior beliefs \(\tilde{\tau}_{i,g}^s\) and \(\tilde{\tau}_{i,g}^b\) with respect to \(\tau_i^{s(c)}\), \(\tau_i^{s(r)}\), and \(\tau_i^b\). Physicians may have more precise signals for some treatment effects types \(\bar{\sigma}\) than others, and the precision of their signals may change with guideline adoption status \(g\).

In the model, CHADS\(_2\) adoption increases the precision of the doctor’s signal of \(\tau_i^{s(c)}\), the CHADS\(_2\)-related variation in stroke treatment effects. The model also allows for the possibility of “distraction effects,” whereby guideline adoption leads physicians to neglect consideration of other decision-relevant factors (i.e. the “cookbook medicine” critique). In the language of the model, distraction effects correspond to physicians forming less precise beliefs about \(\tau_i^{s(r)}\) and \(\tau_i^b\).

### 6.2 Estimating Equation

To estimate policy-relevant parameters from the data, we now map our behavioral model in Equation (10) to a heteroskedastic probit model:

\[
W_i = 1 \left\{ \frac{1}{\sigma_{\varepsilon,g}} \left( \alpha_g^{s(c)} \tau_i^{s(c)}(X_i) + \alpha_g^{s(r)} \tau_i^{s(r)}(X_i) + \alpha_g^{b} \tau_i^{b}(X_i) + \mu_g + f(X_i) + \varepsilon_{i,g} \right) > 0 \right\}. \tag{13}
\]

where \(\varepsilon_{i,g}\) is a normally distributed error with variance \(\sigma_{\varepsilon,g}^2\).

From Equations (10) to (12), the coefficient \(\alpha_g^s\), for treatment effect \(\bar{\sigma} \in \{s(c), s(r), b\}\) measures...
the responsiveness of decisions to a treatment effect and can be interpreted as $\alpha_g^\circ = \beta^\circ \lambda_g^\circ$. Recall that $\beta^\circ$ is the preference weight that physicians place on preventing outcome $\bar{\sigma}$ (stroke or bleed), and $\lambda_g^\circ$ is the signal-to-noise ratio describing how well-informed the physician is about variation in treatment effect $\bar{\sigma}$. $\varepsilon_{i,g}$ includes $\nu_i$ error term from Equation (10) and the “noise” components of posterior beliefs, $\nu_{i,g}^\varepsilon$ and $\nu_{i,g}^b$. In estimation, we normalize $\sigma_{\varepsilon,\text{pre}}^2 = 1$. In our baseline specification, we allow $f(X_i)$ to depend on age, to account for a bias against treating older patients, and on year fixed effects, to capture secular shifts in anticoagulation over time.

Guideline adoption may change the responsiveness to treatment effects in three ways. First, CHADS2 adoption may give physicians more precise information about CHADS2-related variation in stroke treatment effects; this effect increases the responsiveness to treatment effects $\alpha^{s(c)}$ by increasing the doctor’s signal-to-noise ratio for the CHADS2-related variation in stroke treatment effects, i.e. increasing $\lambda^{s(c)}$. Second, because noisy assessment of treatment effects are incorporated into $\varepsilon_{i,g}$, $\sigma_{\varepsilon,g}^2$ may change with guideline adoption. Finally, CHADS2 adoption may distract physicians from considering information about other treatment effects, decreasing the signal-to-noise ratios of doctor’s beliefs about bleed treatment effects $\lambda^b$ or residual variation in stroke treatment effects ($\lambda^{s(r)}$) and thereby leading to smaller estimated coefficients $a^b$ or $\alpha^{s(r)}$, respectively.

To recover and interpret these objects, we require the following assumptions, which we will assess in our results below. First, to recover unbiased (and correctly signed) estimates of coefficients $\alpha_g^\circ$, we require that $\varepsilon_{i,g}$ is uncorrelated with $\tau^\circ(X_i)$. Second, in order to interpret deviations from treating according to treatment effects as worsening strokes or bleeds, we assume that $\nu_i$ does not include unmeasured variation in treatment effects. Finally, in order to identify changes in $\sigma_{\varepsilon,g}$ in our heteroskedastic probit model, we assume that $f(X_i)$ is invariant to guideline adoption. In our baseline specification, we will use age in $f(X_i)$ for this purpose, which assumes that CHADS2 adoption changes treatment decisions with respect to age only through changes in sensitivity to treatment effects.

In estimating Equation (13), we use ML predictions of treatment effects, $\hat{\tau}_{BLP}^{s(c)}(x)$, $\hat{\tau}_{BLP}^{s(r)}(x)$, and $\hat{\tau}_{BLP}^b(x)$, in place of true treatment effects, $\tau^{s(c)}(x)$, $\tau^{s(r)}(x)$, and $\tau^b(x)$. These estimates are measured with error in the sense that they differ from the treatment effects we could obtain with infinite data. Our main concern is that differential measurement error of $\hat{\tau}^{s(c)}(x)$ and $\hat{\tau}^{s(r)}(x)$ may

---

19If guideline adoption sufficiently increases the precision of physician signals, then $\sigma_{\varepsilon,g}^2$ will decrease. However, because $\varepsilon_{i,g}$ includes both noisy assessments and the weight that physicians’ place on them, it is possible that $\varepsilon_{i,g}$ may increase if better information causes physicians to place more weight on their signals, including the noisy component of them. This point follows formally from the microfoundation in Appendix A.1.
differentially attenuate \( \alpha_g^c \) and \( \alpha_g^r \). However, our BLP-adjustment in Section 5.3 of CHADS\(_2\)-related and residual stroke treatment effects provides a means to ensure that \( \alpha_g^c \) and \( \alpha_g^r \) can be interpreted on the same scale. This approach follows a “regression calibration” literature that addresses measurement error (George and Foster, 2000) and also resembles the first stage of “split-sample” instrumental variables approaches in economics (Angrist and Krueger, 1995).

### 6.3 Results

Table 4 reports estimates of \( \tilde{\alpha}_g \), for treatment effect type \( \tilde{\alpha} \in \{s(c), s(r), b\} \) and for each guideline adoption status \( g \in \{\text{never}, \text{pre}, \text{post}\} \), from Equation (13). To facilitate statistical comparisons of the coefficients \( \alpha_g^\tilde{\alpha} \) across adoption states, the estimation takes \( \alpha_g^{\tilde{\alpha}_{\text{pre}}} \) as the baseline, and uses interaction terms to report differences between \( \alpha_g^{\tilde{\alpha}_{\text{post}}} \) or \( \alpha_g^{\tilde{\alpha}_{\text{never}}} \) and this baseline. Since both stroke and bleeding events are undesirable, we expect the sign of coefficients on both stroke and bleeding treatment effects to be negative. In other words, all else equal, physicians should be more likely to treat patients with larger reductions in stroke risk and less likely to treat patients with larger increases in bleeding risk.

Our baseline specification controls for year fixed effects and cubic splines in patient age. Column 1 shows these results. Columns 2 and 3 show alternative specifications controlling for differential time trends in the sensitivity to treatment effects, in order to account for secular trends in overall anticoagulation and awareness of treatment effects.

For physicians who have not adopted the CHADS\(_2\) score (i.e., \( g \in \{\text{never}, \text{pre}\} \)), anticoagulation decisions are already sensitive to the CHADS\(_2\) component of stroke treatment effects and to bleed treatment effects, but they are not sensitive to the residual component of stroke treatment effects. In Appendix Figure A.3, we show that, conditional on CHADS\(_2\) score, treated patients have similar stroke treatment effects before and after guideline adoption. This again suggests that physicians are not selecting on factors that predict stroke treatment effects conditional on CHADS\(_2\) score.\(^{20}\)

Among decisions without CHADS\(_2\) adoption, there are no substantive differences in the responsiveness to treatment effects between physicians who never adopt (i.e., \( g = \text{never} \)) and adopters who have not yet adopted (i.e., \( g = \text{pre} \)). This finding suggests that in the absence of the guideline, eventual adopters are neither lower nor higher skilled than non-adopters at matching patients to appropriate treatment.

Following adoption, physicians put twice as much weight CHADS\(_2\)-related stroke treatment ef-

---

\(^{20}\)This result contrasts with Einav et al. (2019) and Oster (2020), who find that healthier patients select into treatment. In our setting, where physicians are the key decision-maker, patterns of selection might be different.
fects, suggesting guideline adoption improves physicians’ information about this variation in treatment benefits. Further, physicians remain insensitive to residual stroke treatment effects. We find some evidence that physicians become less sensitive to bleed treatment effects following adoption of the CHADS\textsubscript{2} score, although this effect is not statistically significant when controlling more richly for time trends in Column 3. In addition, $\sigma_{e,g}$ changes little with adoption, despite the change in $\alpha_g^{s(c)}$ (see Appendix Table A.6).

We next consider the average marginal effects implied by our model estimates. As shown in Appendix Table A.7, a one-percentage-point reduction in CHADS\textsubscript{2}-related yearly treatment effects leads to a 1.9 percentage points increase in treatment probability prior to CHADS\textsubscript{2} adoption; this effect grows to a 4.3 percentage points increase in treatment probability after CHADS\textsubscript{2} adoption (a 2.4 percentage point difference). On average, low CHADS\textsubscript{2} patients have stroke treatment effects that are 2 percentage points larger in magnitude. After CHADS\textsubscript{2} adoption, we thus expect relative treatment probabilities for low CHADS\textsubscript{2} patients to decline by 4.8 percentage points relative to high CHADS\textsubscript{2} patients. The magnitude of these marginal effects are consistent with our reduced-form results in Section 4.

### 6.4 Interpretation and Robustness

Under the lens of our model, these findings suggest that the CHADS\textsubscript{2} score improves physicians’ information on CHADS\textsubscript{2}-related stroke treatment effects. Specifically, we find that CHADS\textsubscript{2} adoption doubles the precision of physicians’ signal of CHADS\textsubscript{2}-related stroke treatment effects, implying a large increase in the signal-to-noise ratio $\lambda_{\text{pre}}^{s(c)}$ to $\lambda_{\text{post}}^{s(c)}$. In contrast, physicians appear to have little systematic knowledge of residual stroke treatment effects, and adopting the CHADS\textsubscript{2} score has no impact on this. The precision of physicians’ information about CHADS\textsubscript{2}-related stroke treatment effects is much greater than the precision of their information about other sources of treatment effect variation, i.e. $\lambda_g^{s(c)} \gg \lambda_g^{s(r)}$, regardless of $g$.

These estimates imply that doctors do not successfully use variation in stroke treatment effects that is not captured by the CHADS\textsubscript{2} score to improve treatment allocation. In the language of our model, the estimates imply a very low signal-to-noise ratio $\lambda_{g}^{s(r)}$ for residual variation in stroke treatment effects.

We cannot directly test whether physicians are responding to other sources of heterogeneity using characteristics that are unmeasured in the AFI data; however, the insensitivity of physician decisions to any of the residual variation in stroke treatment effects suggests that there may be little selection
of this sort. By design, the AFI studies record a wide array of clinical characteristics that expert clinicians predicted might drive variation in risk and treatment effects. We demonstrated that these factors indeed predict wide variation in stroke treatment effects beyond that captured by the CHADS\textsuperscript{2} score. Nevertheless, treatment decisions by VHA physicians are unresponsive to all of the measured variation in stroke treatment effects beyond those factors codified into the CHADS\textsuperscript{2}.

This evidence suggests that guideline adoption may provide important informational benefits. However, three factors highlight the potential limits of adoption. First, we find some evidence of distraction effects which may limit the degree to which CHADS\textsuperscript{2} adoption reduces strokes per induced bleed. Second, although we see a large relative increase in physicians’ responsiveness to CHADS\textsuperscript{2}-related treatment effects, we see no significant reduction in \( \sigma_{e,g} \) with CHADS\textsuperscript{2} adoption. This result suggests that uncertainty about CHADS\textsuperscript{2}-related treatment effects is responsible for only a small share of variation in treatment decisions. Third, even with adoption of the CHADS\textsuperscript{2} score, physicians continue to be less inclined to treat older patients (who also have higher CHADS\textsuperscript{2} scores), and this behavior cannot be explained by treatment effects.\textsuperscript{21}

Before we take our results to counterfactual simulations, we can use the rich set of covariates in the VHA data to assess some of our key assumptions. Recall that our baseline model already accounts for the role of many variables that predict treatment effect heterogeneity and may enter physician decisionmaking, including salient biomarkers (blood pressure, hemoglobin), patient history (stroke, heart attack, angina), as well as key comorbidities and demographic variables. In Appendix A.4, we describe many additional patient characteristics that may influence anticoagulation decisions but are not available in the VHA data, and which we now add to our analysis. These variables extensively cover a wide array of factors suggested by clinicians and prior researchers to influence treatment decisions. Importantly, these include many variables related to frailty and fall risk, including past reports of dizziness, muscle weakness, prior injuries (fractures, head injuries), and risky conditions (Parkinson’s Disease, neuropathy, arthritis, vision problems). We also cover variables that were later included into the HAS-BLED guideline to assess bleeding risk if anticoagulated (liver disease, renal failure, alcohol abuse, prior bleeds). Other variables include a full set of Elixhauser comorbidities, physician specialization, and variables that predict patients’ ability to comply with warfarin monitoring.

In Panel A of Figure A.4, we investigate the robustness of our findings to these additional control variables. Enriching the control variables does not substantively change the estimated effect of

\textsuperscript{21}A similar pattern has been documented in the setting of heart attack care by (Currie et al., 2016): physicians avoid treating older patients, even when they would benefit from treatment.
CHADS\textsubscript{2} adoption on treatment decisions. Specifically, the proportional change in signal-to-noise ratio of physicians’ beliefs about CHADS\textsubscript{2}-related variation in stroke treatment effects after guideline adoption, $\lambda_{\text{pre}}^{\text{pre}} / \lambda_{\text{post}}^{\text{post}}$, does not vary much as we progressively add these additional covariates to the model.

Next, we explore whether the residual variation in treatment decisions (conditional on estimated treatment effects) can be explained by the variables described above that might predict treatment decisions but are available only in the observational VHA data and not in the RCT data from AFI. In Panel B of Figure A.4, we show that these additional variables do not systematically explain a large fraction of treatment decisions and therefore cannot explain the high rates guideline non-adherence.\footnote{To the degree that one interprets the results in Panel A as a nonlinear analogue of the test in Altonji et al. (2008), one might argue that panel B suggests that this test has limited power in the sense of Oster (2019). The test in Panel A is of direct interest because the covariates we include account for specific normative justifications that physicians give for non-adherence, but it is not especially informative about other unobservable characteristics in the Oster (2019) sense.}

Even as we control for detailed patient characteristics, we find little increase in the explained share of variance in treatment decisions.

This evidence, combined with the important fact that physicians do not even respond to measured variation in stroke treatment effects (beyond the factors captured in the CHADS\textsubscript{2}), suggests that departures from treating according to measured treatment effects is unlikely to be explained by unmeasured variation in treatment effects. Instead, these deviations might represent practice style variation across physicians or idiosyncratic decision-making within each physician.\footnote{Finally, note that selection on unobservable determinants of treatment effects is immaterial for our counterfactual analyses comparing strict adherence with random treatment decisions. These analyses consider treatment rules based only on observable characteristics, for which CATEs are the relevant objects. If doctors did have private information about treatment effects, our counterfactuals will underestimate the benefits of the status quo, but still correctly assess the impact of guideline adherence relative to random treatment.}

### 7 Counterfactual Adoption and Adherence

Based on our ML-predicted treatment effects in Section 5 and our analysis of physician decision-making in Section 6, we simulate outcomes under counterfactual scenarios of guideline adoption and adherence. When discussing counterfactual outcomes, it is useful to compare outcomes to a few benchmarks. Treating all patients with newly diagnosed atrial fibrillation in the VHA would prevent 400 strokes (hereafter, “preventable strokes”) and induce 277 bleeding events (hereafter, “inducible bleeds”) per 10,000 patients after one year.

In Figure 6 and Table 5, we show key results on prevented strokes and induced bleeds under counterfactual scenarios. We first show that status quo physician decisions are only slightly better than
random anticoagulation of atrial fibrillation patients: physicians prescribe anticoagulation to 49.8% of patients and prevent 49.8% of preventable strokes but induce 48.4% of inducible bleeds. That is, status quo decisions prevent only \( \frac{49.8\%}{48.4\%} - 1 \approx 3\% \) more strokes per bleed than random decisions with the same induced bleeds. While we found in Section 6.3 that physicians are sensitive to treatment effects, the benefits of this sensitivity are offset by the tendency not to treat older patients who often have desirable ratios of stroke to bleed treatment effects. We will later revisit this issue with analyses that reallocate anticoagulation only within age bins.

Next, we consider counterfactual outcomes under scenarios varying the extensive margin of guideline adoption. Adoption of the CHADS\(_2\) score had relatively muted effects on outcomes. Under the counterfactual scenario of no CHADS\(_2\) adoption, 49.7% of patients would be treated, preventing 49.2% of preventable strokes and inducing 48% of inducible bleeds (i.e. preventing 2.7% more strokes per bleed than a random allocation). Universal CHADS\(_2\) adoption increases treatment to 50.2% of patients, preventing 51.3% of preventable strokes and inducing 49.5% of inducible bleeds (preventing 3.7% more strokes per bleed than random).

We can also use the model to simulate adoption of a more comprehensive guideline revealing all information about stroke treatment effects. We assume that physicians who have adopted this guideline will become as well informed about residual variation in stroke treatment effects \( \tau^{s(r)(x)} \) as they are about CHADS\(_2\)-related stroke treatment effects \( \tau^{s(c)(x)} \) after CHADS\(_2\) adoption. (More specifically, in our counterfactual, we set the signal-to-noise ratios \( \lambda^{s(r)} = \lambda^{s(c)}_{\text{post}} \), so that the coefficient \( \alpha^{s(r)} = \alpha^{s(c)}_{\text{post}} \).) In this scenario, at a treatment rate of 49.8%, physicians prevent 55.5% of preventable strokes and induce 48.4% of inducible bleeds (preventing 14.8% more strokes per bleed than random). A more comprehensive guideline outperforms the CHADS\(_2\) score.

We then turn to scenarios involving strict adherence to a guideline. Treatment decisions under these scenarios strictly follow an ordering according to guideline recommendations, and we remove any tendency not to treat older patients and the substantial idiosyncratic variation in treatment decisions. Each guideline implies a “score” that we use to order patients; patients with the same score (e.g., patients with the same CHADS\(_2\) score for the CHADS\(_2\) guideline) are randomly ordered. We evaluate the performance of adhering to each guideline-implied ordering by a set of counterfactual outcomes, moving from no patients treated to all patients treated. Under the assumption that the costs

\[ \text{Our model also does not identify how much a more comprehensive guideline would reduce noise in treatment choices and thus reduce } \sigma_{r,\text{post}} \text{, but we can bound this effect. Our results are not sensitive to the bounds. We discuss this detail, as well as assumptions about distraction effects, in Appendix A.2.} \]
of treatment and monitoring are negligible relative to the clinical benefits,\textsuperscript{25} two guideline orderings can be welfare-ranked if one guideline prevents more strokes than the other guideline, for any fixed number of induced bleeds.

Compared to expanding adoption, policies that achieve strict adherence to guidelines produce much better outcomes. Holding bleeds fixed at the status quo level, strict adherence to the CHADS\textsuperscript{2} score prevents 56\% of preventable strokes. In other words, strict adherence to the CHADS\textsuperscript{2} prevents 17\% more strokes-per-bleed than was achieved with universal CHADS\textsuperscript{2} adoption. Adherence to a score based on full stroke treatment effects performs better still, preventing 68.5\% of preventable strokes for the same number of bleeds.

Finally, we consider adherence to an optimal guideline that recommends treatment according to the ratio of full stroke and bleed treatment effects, or $-\frac{\hat{\tau}^s_{BLP}(x)}{\hat{\tau}^b_{BLP}(x)}$. Treatment orderings based on this ratio should optimize any linear objective function depending on strokes and bleeding events.\textsuperscript{26} Ordering based on the complete ratio can prevent 73\% of preventable strokes, or 47\% more strokes than under the status quo, while holding induced bleeds fixed at the status quo level.

In additional counterfactuals, we investigate the role of weighting vs. the number of variables considered. In Appendix Figure 6, we show that adherence to the CHADS\textsuperscript{2}VASc guideline prevents fewer strokes at any given number of bleeds than strict adherence to the CHADS\textsuperscript{2} score (i.e. it performs worse than CHADS\textsuperscript{2} score). Our model suggests that vascular disease is an important predictor of stroke treatment effects, but the CHADS\textsuperscript{2}VASc guideline gives vascular disease too much weight relative to other variables.\textsuperscript{27} Thus, more comprehensive guidelines are not always better. More comprehensive guidelines can improve outcomes, but only if the relevant factors are weighted appropriately given treatment effects.

To understand the benefits of more comprehensive guidelines relative to the CHADS\textsuperscript{2} score, we also consider an “adjusted CHADS” score that assigns integers to approximate the ratio of stroke treatment effects to bleed treatment effects, $-\frac{\hat{\tau}^s_{BLP}(x)}{\hat{\tau}^b_{BLP}(x)}$, with each of the five conditions in the original CHADS\textsuperscript{2} score. Holding induced bleeds fixed at the status quo level, adherence to this “adjusted CHADS” guideline prevents 62\% of preventable strokes, about one-third of the difference between the CHADS\textsuperscript{2} and the optimal guideline. In this sense, about one-third of the benefits of our

\textsuperscript{25}This assumption is standard in the existing medical literature on anticoagulation, e.g. Singer et al. (2009).

\textsuperscript{26}For an objective function \(u_i = \beta^s x^s_i + \beta^b x^b_i\), the optimal rule is to treat any patient such that $-\hat{\tau}^s_{BLP}(x)/\hat{\tau}^b_{BLP}(x) > \beta^b / \beta^s$. Note the similarity with Equation (10). In that model, an agent will adhere fully to a ratio rule with observed treatment effects if $f(x_i) + v_i = 0$ for all $i$. We give details in Appendix A.3.

\textsuperscript{27}In the interest of simplicity, most of the existing CHADS\textsuperscript{2} weights were unchanged in the CHADS\textsuperscript{2}VASc score (all variables other than age), but additional variables were added. Vascular disease was given a weight of “1”, the lowest weight available in the score. This weight was still too large and reduced the performance of the score.
optimal guideline come from better weighting and two-thirds come from including more variables.

The tendency not to treat old people cannot be rationalized by a lower value of a statistical life, since that would bear equally on strokes and bleeds, but it could be rationalized if doctors believed that the relative welfare cost of strokes and bleeds differed for older patients or if the costs of monitoring were more substantial at older ages. In Appendix Figure A.6 and Appendix Table A.8, we explore outcomes in counterfactual scenarios that hold fixed the age distribution (in five-year bins) of treated patients. Observed physician decisions are better than random, but only by a small amount. The benefits of strict guideline adherence are slightly attenuated when constraining the age distribution of treated patients but comparable in magnitude to what we find in the unconstrained scenario. For example, adherence to the optimal ratio guideline can still prevent 44% more strokes than the status quo holding bleeds fixed and maintaining the age distribution of treated patients.

8 Conclusion

Our findings suggest that evidence-based clinical guidelines have the potential to improve patient health outcomes. The CHADS$_2$ score shifted physician behavior and likely prevented a small number of additional strokes while inducing an even smaller number of additional bleeds. Adoption of more comprehensive guidelines that incorporates all of the variables that predict stroke treatment effects would have larger benefits. Stricter adherence to existing or novel treatment rules produces much larger gains than adoption with discretionary adherence. Strict adherence to an optimal treatment rule that minimizes strokes per bleed can prevent 47% more strokes without increasing the number of induced bleeds.

Our results suggest three important lessons for the use of guidelines in clinical care. First, the extensive margin of guideline adoption, in which physicians are aware of the guideline but exercise discretion in how to use it, achieves only a fraction of the benefits of greater intensive margin adherence. Second, incorporating more variables into guidelines can improve outcomes, but only if they are weighted properly. We find that optimally weighting the CHADS$_2$ variables achieves about one-third of the benefits of an optimal guideline with all available information. The CHA$_2$DS$_2$-VASc score provides a cautionary tale of a more complex score that underperforms relative to the simpler CHADS$_2$ score due to misweighting. Third, improving the prediction of treatment effects for a single outcome may underperform relative to treatment rules that balance a trade-off between different outcomes. An optimal rule combining information on stroke and bleed treatment effects outperforms
one based on strokes alone. The best algorithms are designed to match a social objective function (Obermeyer et al., 2019).

Many policy instruments are available to promote adherence. On the less invasive side, in-person campaigns to educate and persuade physicians to adhere to guidelines, as well as order sets and electronic reminders can make more salient the costs of departing from guidelines (Piccini et al., 2019). Alerting physicians if their adherence rates are low relative to peers could also shift behavior (Sacarny et al., 2018). More directly, pay for performance incentives could reward physicians whose treatment behavior accords with guidelines (Werner et al., 2011), and insurers could impose hassle costs on physicians to justify treatment decisions which do not comply with guidelines (e.g. failing to treat patients with higher stroke to bleed ratios than other treated patients) (Dillender, 2018). Best practices for implementing guidelines in clinical decision support (CDS) IT systems call for generating evidence for their external validity (Bates et al., 2020). An alternative way to increase adherence to new and existing guidelines may be to generate better evidence for their validity as we seek to do here, increasing the strength of the signal that guidelines provide.

Our results incorporate more information to estimate treatment effects than has been previously considered, but they only scratch the surface of what is possible. Machine-based algorithms could continue to learn both from additional trials and from observational data, in order to create more powerful predictors of treatment effects. While there remain logistical challenges to the widespread integration of machine-based algorithms into health IT systems (Kawamoto and McDonald, 2020), these are likely to be lessened as data integration and methods of validation in healthcare becomes more commonplace. As such algorithms are implemented, healthcare markets will be reshaped as physicians take on fundamentally different roles (Autor et al., 2003).

References


Figure 1: Anticoagulation Trends by CHADS₂ Score

Notes: This figure shows the fraction of atrial fibrillation patients treated with anticoagulation over time, for three groups of patients by CHADS₂ score. The sample reflect patients with newly diagnosed atrial fibrillation in the VHA, and anticoagulation treatments are defined as prescriptions within 90 days of initial diagnosis. Table 2 provides further details about the sample selection.
Figure 2: Diffusion of the CHADS\textsubscript{2} Score

Notes: This figure shows the fraction of patients a given year with physicians who either mention the CHADS\textsubscript{2} score in the note for the index patient or have mentioned the CHADS\textsubscript{2} score in either the note for the index patient or in a previous note. We identify mentions by searching the note text for the phrase chads (not case-sensitive). We consider any physician who has mentioned the the CHADS\textsubscript{2} score in the current note or in a previous note as having adopted the CHADS\textsubscript{2} guideline, shown in the solid line. The dashed line reflects the rate of mentions in the index patient’s note. The sample reflect patients with newly diagnosed atrial fibrillation in the VHA. Table 2 provides further details about the sample selection.
Figure 3: Treatment Decisions and CHADS\textsubscript{2} Adoption

A. Trends Relative to CHADS\textsubscript{2} Adoption

![Graph showing trends relative to CHADS\textsubscript{2} adoption.]

B. Event Study Estimates

![Graph showing event study estimates.]

Notes: Panel A displays the fraction of atrial fibrillation patients treated with anticoagulation in each year relative to CHADS\textsubscript{2} adoption for physicians who eventually adopt the CHADS\textsubscript{2} score. Panel B shows regression coefficients and 95% confidence intervals from Equation (1), run separately for patients with CHADS\textsubscript{2} \in \{0, 1\} and for patients with CHADS\textsubscript{2} \geq 2. The 12-month period prior to the physician’s first CHADS\textsubscript{2} mention is normalized to 0. The regression sample includes 104,585 VHA patients who either are treated within 5 years of their physician’s observed CHADS\textsubscript{2} adoption or are treated by a non-adopting physician.
Figure 4: Distribution of Treatment Effects Across VHA Patients

Notes: This figure displays histograms of stroke and bleed treatment effects in the VHA sample. Conditional average treatment effect (CATE) predictions are trained and validated by using causal forest methods, described in Section 5, applied to RCT data in the AFI database. We use the causal forest rules to calculate CATEs as a function of patient characteristics for each patient in the VHA data.
Figure 5: Treatment Effects by CHADS$_2$ Score

A. Stroke Treatment Effects

B. Bleed Treatment Effects

Notes: This figure shows box plots for the distribution of treatment effects by CHADS$_2$ score in the VHA data. Stroke treatment effects are shown in Panel A; bleed treatment effects are shown in Panel B. Bounds on the box plot are at the 25th and 75th percentile, with the median marked with a horizontal line. Whiskers extend to the 5th and 95th percentiles.
Notes: This figure shows strokes prevented and bleeds induced by anticoagulation in counterfactual scenarios. Strokes prevented per 10,000 patients are shown on the y-axis, and bleeds induced per 10,000 patients are shown on the x-axis. Both panels display outcomes under a random treatment allocation, ranging from 0% of patients treated (top-left corner of Panel A) to 100% of patients treated (bottom-right corner of Panel A). Panel A shows outcomes under counterfactual strict adherence to various guideline rules. Each rule implies a patient sorting, and the curves indicate counterfactual outcomes ranging from treating 0% to 100% of patients. “Sort by adjusted CHADS score” involves sorting by an integer score based on the CHADS\textsubscript{2} component conditions (see Table 1) but predicting the ratio of stroke treatment effect to bleed treatment effect. “Sort by TE ratio” sorts by the ratio of stroke treatment effect to bleed treatment effect. Crosses indicate the points where 50% of patients are treated. Panel B shows an inset area and plots outcomes for counterfactual adoption (i.e., imperfect adherence) scenarios.
Table 1: CHADS$_2$ Score and Treatment Recommendations

<table>
<thead>
<tr>
<th>CHADS$_2$ Components</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of congestive heart failure</td>
<td>1</td>
</tr>
<tr>
<td>History of hypertension</td>
<td>1</td>
</tr>
<tr>
<td>History of diabetes mellitus</td>
<td>1</td>
</tr>
<tr>
<td>Aged 75 or older</td>
<td>1</td>
</tr>
<tr>
<td>Previous stroke or transient ischemic attack</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score of 2 or greater: high risk of stroke;</td>
</tr>
<tr>
<td>oral anticoagulant recommended</td>
</tr>
<tr>
<td>Score of 1: moderate risk of stroke;</td>
</tr>
<tr>
<td>oral anticoagulant considered</td>
</tr>
<tr>
<td>Score of 0: low risk of stroke;</td>
</tr>
<tr>
<td>oral anticoagulant not recommended</td>
</tr>
</tbody>
</table>

*Notes:* This table describes the CHADS$_2$ score used to assess stroke risk among patients with atrial fibrillation. The score is based on evidence developed by Gage et al. (2001, 2004). In the bottom panel, the table also summarizes the 2006 ACC and 2008 ACCP guideline treatment recommendations based on the CHADS$_2$ score, published in Members et al. (2006); Hirsh et al. (2008).
### Table 2: VHA Sample Selection

<table>
<thead>
<tr>
<th>Sample step</th>
<th>Description</th>
<th>Observations</th>
<th>Dropped</th>
<th>Remaining</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Identify potentially new atrial fibrillation patients</td>
<td>Identify candidate patients with a diagnosis of atrial fibrillation not previously diagnosed in the last three years.</td>
<td></td>
<td>844,312</td>
<td></td>
</tr>
<tr>
<td>2. Prescription restriction</td>
<td>Keep patients who had a prescription filled at the VA within the last year. Drop patients who had a prior anticoagulation prescription.</td>
<td>290,214</td>
<td>554,098</td>
<td></td>
</tr>
<tr>
<td>3. Confirmed atrial fibrillation diagnosis</td>
<td>Keep patients who had an EKG within 30 days before or after initial diagnosis and a second atrial fibrillation diagnosis recorded 30-365 days after index visit.</td>
<td>254,164</td>
<td>299,934</td>
<td></td>
</tr>
<tr>
<td>4. PCP or cardiologist visit</td>
<td>Keep patients who had a PCP or cardiologist visit up to 90 days after the index visit. The earliest such visit identifies the attributed physician. Require that the attributed physician wrote at least one non-warfarin prescription for the patient within one year (before or after).</td>
<td>135,395</td>
<td>164,539</td>
<td></td>
</tr>
<tr>
<td>5. Physicians with sufficient sample</td>
<td>Keep patients attributed to a physician with at least 30 atrial fibrillation patients and has written at least one warfarin prescription in the unrestricted sample defined in step #1.</td>
<td>32,868</td>
<td>131,671</td>
<td></td>
</tr>
<tr>
<td>6. Drop observations with missing variables</td>
<td>Keep patients with non-missing demographics, comorbidities, and clinical information.</td>
<td>18,401</td>
<td>113,270</td>
<td></td>
</tr>
</tbody>
</table>

*Note:* This table describes key VHA sample selection steps, the observations dropped, and the observations remaining after each step.
Table 3: Summary Statistics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>VHA Data</th>
<th>AFI Database</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adopting Physician</td>
<td>Non-Adopting Physician</td>
</tr>
<tr>
<td>Treated with anticoagulation</td>
<td>0.50</td>
<td>0.50</td>
</tr>
<tr>
<td>Male</td>
<td>0.99</td>
<td>0.99</td>
</tr>
<tr>
<td>Age (years)</td>
<td>74.0</td>
<td>74.2</td>
</tr>
<tr>
<td></td>
<td>(10.0)</td>
<td>(9.7)</td>
</tr>
<tr>
<td>Stroke treatment effect</td>
<td>−0.041</td>
<td>−0.040</td>
</tr>
<tr>
<td></td>
<td>(0.025)</td>
<td>(0.024)</td>
</tr>
<tr>
<td>Bleed treatment effect</td>
<td>0.028</td>
<td>0.028</td>
</tr>
<tr>
<td></td>
<td>(0.010)</td>
<td>(0.024)</td>
</tr>
<tr>
<td>CHADS2 components:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>0.16</td>
<td>0.15</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.84</td>
<td>0.83</td>
</tr>
<tr>
<td>Age ≥ 65</td>
<td>0.51</td>
<td>0.52</td>
</tr>
<tr>
<td>Diabetes</td>
<td>0.36</td>
<td>0.35</td>
</tr>
<tr>
<td>Previous stroke</td>
<td>0.15</td>
<td>0.14</td>
</tr>
<tr>
<td>Number of physicians</td>
<td>2,950</td>
<td>2,802</td>
</tr>
<tr>
<td>Number of patients</td>
<td>64,592</td>
<td>48,678</td>
</tr>
</tbody>
</table>

Notes: This table reports mean and standard deviations of characteristics of patients in the VHA data and in the AFI database. Standard deviations are shown in parentheses. Columns 1 and 2 show characteristics of patients in the VHA data, with sample selection steps described in Table 2, for patients with physicians who have adopted the CHADS2 guideline and for those with physicians who have adopted the guideline, respectively. Column 3 shows characteristics of patients from the AFI database.
Table 4: Probit Estimates

<table>
<thead>
<tr>
<th></th>
<th>Dependent Variable: Anticoagulant Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td>(2)</td>
</tr>
<tr>
<td>(3)</td>
<td></td>
</tr>
<tr>
<td>CHADS$<em>2$-related stroke treatment effect, $\hat{g}^{s(c)}</em>{BLP}(x)$</td>
<td></td>
</tr>
<tr>
<td>Pre-adoption baseline, $\alpha^{s(c)}_{pre}$</td>
<td>$-4.705^{***}$</td>
</tr>
<tr>
<td></td>
<td>$(0.698)$</td>
</tr>
<tr>
<td>Post-adoption difference, $\alpha^{s(c)}<em>{post} - \alpha^{s(c)}</em>{pre}$</td>
<td>$-6.078^{***}$</td>
</tr>
<tr>
<td></td>
<td>$(1.097)$</td>
</tr>
<tr>
<td>Never-adopter difference, $\alpha^{s(c)}<em>{never} - \alpha^{s(c)}</em>{pre}$</td>
<td>$0.941$</td>
</tr>
<tr>
<td></td>
<td>$(0.711)$</td>
</tr>
<tr>
<td>Residual stroke treatment effect, $\hat{g}^{s(r)}_{BLP}(x)$</td>
<td></td>
</tr>
<tr>
<td>Pre-adoption baseline, $\alpha^{s(r)}_{pre}$</td>
<td>$0.609^{**}$</td>
</tr>
<tr>
<td></td>
<td>$(0.308)$</td>
</tr>
<tr>
<td>Post-adoption difference, $\alpha^{s(r)}<em>{post} - \alpha^{s(r)}</em>{pre}$</td>
<td>$-0.925^*$</td>
</tr>
<tr>
<td></td>
<td>$(0.481)$</td>
</tr>
<tr>
<td>Never-adopter difference, $\alpha^{s(r)}<em>{never} - \alpha^{s(r)}</em>{pre}$</td>
<td>$0.0430$</td>
</tr>
<tr>
<td></td>
<td>$(0.404)$</td>
</tr>
<tr>
<td>Bleed treatment effect, $\hat{g}^{b}_{BLP}(x)$</td>
<td></td>
</tr>
<tr>
<td>Pre-adoption baseline $\alpha^{b}_{pre}$</td>
<td>$-3.272^{***}$</td>
</tr>
<tr>
<td></td>
<td>$(0.793)$</td>
</tr>
<tr>
<td>Post-adoption difference, $\alpha^{b}<em>{post} - \alpha^{b}</em>{pre}$</td>
<td>$2.462^*$</td>
</tr>
<tr>
<td></td>
<td>$(1.280)$</td>
</tr>
<tr>
<td>Never-adopter difference, $\alpha^{b}<em>{never} - \alpha^{b}</em>{pre}$</td>
<td>$1.065$</td>
</tr>
<tr>
<td></td>
<td>$(1.037)$</td>
</tr>
<tr>
<td>Year fixed effects, age spline controls</td>
<td>Yes</td>
</tr>
<tr>
<td>Differential trends on treatment effects</td>
<td>No</td>
</tr>
<tr>
<td>Treatment effects interacted with year identities</td>
<td>No</td>
</tr>
<tr>
<td>Number of observations</td>
<td>113,270</td>
</tr>
</tbody>
</table>

Notes: This table reports estimates from probit regressions of anticoagulation treatment decisions, as specified in Equation (13). Key regressors of interest are causal forest predictions of CATEs: CHADS$_2$-related stroke treatment effects, or $\hat{g}^{s(c)}_{BLP}(x)$; residual stroke treatment effects, , or $\hat{g}^{s(r)}_{BLP}(x)$; and bleed treatment effects, or $\hat{g}^{b}_{BLP}(x)$. Column 2 includes linear trends interacted with each of these treatment effects. Column 3 includes three-way interactions of (i) each of the treatment effects, (ii) indicators for two-year periods, and (iii) adoption status. These probit models allow that $\sigma_{c,g}$ may vary with adoption status and year fixed effects, reported in Appendix Table A.6. Standard errors are clustered at the physician level. *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$. 

46
Table 5: Counterfactual Treatment Decisions and Outcomes

<table>
<thead>
<tr>
<th>A: Benchmarks</th>
<th>Treated Patients</th>
<th>Strokes Prevented</th>
<th>Bleeds Induced</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observed treatment choices</td>
<td>49.8%</td>
<td>199</td>
<td>134</td>
</tr>
<tr>
<td>Randomly assigned treatment</td>
<td>49.8%</td>
<td>199</td>
<td>138</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B: Guideline Adoption</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No CHADS(_2) adoption</td>
<td>49.7%</td>
<td>197</td>
<td>133</td>
</tr>
<tr>
<td>Universal CHADS(_2) adoption</td>
<td>50.2%</td>
<td>205</td>
<td>137</td>
</tr>
<tr>
<td>Universal adoption of stroke TE guideline</td>
<td>49.8%</td>
<td>222</td>
<td>134</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C: Strict Guideline Adherence, Fixed Bleeds Induced</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Strict adherence to CHADS(_2)</td>
<td>44.6%</td>
<td>224</td>
<td>134</td>
</tr>
<tr>
<td>Strict adherence to adjusted CHADS score</td>
<td>58.2%</td>
<td>247</td>
<td>134</td>
</tr>
<tr>
<td>Strict adherence to stroke TE guideline</td>
<td>45.1%</td>
<td>274</td>
<td>134</td>
</tr>
<tr>
<td>Strict adherence to TE-ratio guideline</td>
<td>55.1%</td>
<td>292</td>
<td>134</td>
</tr>
</tbody>
</table>

Notes: This table reports treatment rates and patient outcomes in counterfactual adoption and adherence scenarios for patients in the VHA data. Outcomes of strokes prevented and bleeds induced are reported per 10,000 patients. Panel A reports treatment rates and outcomes under the status quo, which we observe in our data, and in a counterfactual assignment of the same number of treatments to random patients. Panel B reports treatment rates and outcomes under counterfactual adoption scenarios, assuming adherence implied by our structural model in Equation (13). “Universal adoption of stroke TE guideline” refers to guideline adoption in which physicians become equally informed of CHADS\(_2\)-related and residual stroke treatment effects (i.e., \(\hat{\gamma}^{(c)}_{BLP}(x)\) and \(\hat{\gamma}^{(r)}_{BLP}(x)\)). Panel C reports treatment rates and outcomes under patient orderings according to scores implied by counterfactual strict adherence to different guidelines. Patients with the same score are randomly ranked. “Strict CHADS\(_2\) adherence” orders patients by their CHADS\(_2\) score. “Strict adherence to adjusted CHADS score” orders patients by a point system approximating \(\hat{\gamma}^{(c)}_{BLP}(x)/\hat{\gamma}^{(r)}_{BLP}(x)\) by CHADS\(_2\) indicators in Table 1. “Strict adherence to stroke TE guideline” orders patients by \(\hat{\gamma}^{(c)}_{BLP}(x)/\hat{\gamma}^{(r)}_{BLP}(x)\). “Strict adherence to TE-ratio guideline” orders patients by \(\hat{\gamma}^{(c)}_{BLP}(x)/\hat{\gamma}^{(r)}_{BLP}(x)\).
Online Appendix

“Mastering the Art of Cookbook Medicine: Machine Learning, Randomized Trials, and Misallocation”

Jason Abaluck
Leila Agha
David Chan
Daniel Singer
Diana Zhu

October 16, 2020
A.1 Bayesian Model of Decision-Making

In this appendix, we describe in greater detail the Bayesian model of decision-making specified in Equation (10), which we restate here:

\[ W_i = 1 \left\{ \beta^s \tilde{x}_{i,g}^s + \beta^b \tilde{x}_{i,g}^b + f(X_i) + v_i > 0 \right\}, \]

focusing on the Bayesian posterior beliefs about treatment effects: \( \tilde{\tau}_{i,g}^s \) and \( \tilde{\tau}_{i,g}^b \). Recall that \( g \) denotes the adoption status of the physician. Adoption status may change the informativeness of physician beliefs about treatment effects.

A.1.1 Component Treatment Effects, Signals, and Beliefs

Treatment effects and physician beliefs depend on patient characteristics, which we may orthogonalize into components \( k \in K \). We can conceptualize each principal component as implying additional (orthogonal) information about treatment effects. Specifically, assume that treatment effects are normally distributed and comprise component treatment effects that are also normally distributed:

\[ \tau_{i,k}^o \sim N \left( \bar{\tau}_{k}^o, \sigma^2_{\tau (o),k} \right), \]  

for outcome \( o \) and each \( k \in K \). We assume that physicians know the moments of each component treatment effect \( \left( \bar{\tau}_k, \sigma^2_{\tau (o),k} \right)_{k=1}^K \).

For each component \( k \), physicians receive a noisy signal of the underlying treatment effect, \( \tilde{\tau}_{i,k}^o \):

\[ \tilde{\tau}_{i,g,k} = \tau_{i,k}^o + \epsilon_{i,g,k}^o, \]  

where \( \epsilon_{i,g,k}^o \) is a normally distributed noise term with variance \( \sigma^2_{\epsilon (o),g,k} \). or \( \epsilon_{i,g,k}^o \sim N \left( 0, \sigma^2_{\epsilon (o),g,k} \right) \).

Note the dependence of signals on \( g \). This models the possibility that adoption status may change the quality of information that physicians receive about treatment effects.

Given prior beliefs and the noisy signals, physicians form posterior beliefs, \( \tilde{\tau}_{i,g,k}^o \). Specifically,

\[ \tilde{\tau}_{i,g,k}^o = \lambda_{g,k} \tilde{\tau}_{i,g,k}^o + (1 - \lambda_{g,k}) \bar{\tau}_{k}^o, \]  

where \( \lambda_{g,k} = \frac{\sigma^2_{\epsilon (o),g,k}}{\sigma^2_{\tau (o),k} + \sigma^2_{\epsilon (o),g,k}} \) is the signal-to-noise ratio of the \( k \)th component.

A.1.2 Regression Interpretation

The relationship between posterior beliefs and signals in Equation (A.3) can be interpreted as a regression of posterior beliefs on signals. This relationship may also be interpreted as a regression

\[ \text{Our model in Equation (10) allows for potentially non-Bayesian beliefs that can shift decision-making via } f(X_i) \text{ and } v_i. \text{ In order to study the effect of information in a Bayesian framework, we compartmentalize the two components of the model and consider the first component, described in this appendix, as Bayesian.} \]
of posterior beliefs on true treatment effects, since the noise component of signals is orthogonal to
treatment effects:

\[ \tau_{i,g,k}^o = \lambda_{g,k} \tau_{i,g,k}^o + (1 - \lambda_{g,k}^o) \tau_k^o \]

where the second line uses the definition of the signal in Equation (A.2). In other words, a unit
increase in the treatment effect \( \tau_{i,k}^o \) should increase posterior beliefs by \( \lambda_{g,k}^o \).

We may use this framework to consider the relationship between overall treatment effects, overall
signals, and overall posterior beliefs, aggregated across components \( k \in K \). These overall objects are,
respectively, \( \tau_{i,g}^o \equiv \sum_{k \in K} \tau_{i,g,k}^o \); \( \tau_{i,g}^o = \sum_{k \in K} \tau_{i,g,k}^o \); and \( \tilde{\tau}_{i,g}^o = \sum_{k \in K} \tilde{\tau}_{i,g,k}^o \). Substituting the definition of
the component signals from Equation (A.3), we may also state the overall posterior belief as

\[ \tilde{\tau}_{i,g}^o = \sum_{k \in K} \left( \lambda_{g,k} \tau_{i,g,k}^o + (1 - \lambda_{g,k}^o) \tau_k^o \right). \]  

(A.4)

We now consider the overall signal-to-noise ratio in a regression predicting the overall posterior
belief using the signal:

\[ \tilde{\tau}_{i,g}^o = \lambda_{g} \tilde{\tau}_{i,g}^o + (1 - \lambda_{g}^o) \tau^o. \]  

(A.5)

Using Equation (A.4) for \( \tilde{\tau}_{i,g}^o \) and the definition of the overall signal for \( \tilde{\tau}_{i,g}^o \), the coefficient \( \lambda_{g}^o \) in this
regression is

\[ \lambda_{g}^o = \frac{\text{Cov}(\tilde{\tau}_{i,g}^o, \tau^o)}{\text{Var}(\tilde{\tau}_{i,g}^o)} = \frac{\sum_{k \in K} \lambda_{g,k} \text{Var}(\tau_{i,g,k}^o)}{\sum_{k \in K} \text{Var}(\tau_{i,g,k}^o)} \]

(A.6)

\[ = \frac{\sum_{k \in K} \sigma_{\tau(o,g,k)}^2}{\sum_{k \in K} \left( \sigma_{\tau(o,g,k)}^2 + \sigma_{\epsilon(o,g,k)}^2 \right)}. \]  

(A.7)

Equation (A.6) reveals that the overall signal-to-noise ratio, \( \lambda_{g}^o \), can be thought of as a variance-
weighted average of the component signal-to-noise ratios, \( \lambda_{g,k}^o \). Equation (A.7) shows that a posterior
belief formed directly from the aggregate signal, as in Equation (A.5), will have the same signal-to-
noise ratio as a posterior belief aggregated from component posterior beliefs, as in Equation (A.4).

A.1.3 CHADS\textsubscript{2} and Residual Treatment Effects

We are now in a position to state posterior beliefs as in Equations (11) and (12). For strokes, we
can separate the set of components \( K_c \) that predict CHADS\textsubscript{2}-related treatment effects and \( K \setminus K_c \)
components that predict residual treatment effects. We expect that the component posterior beliefs
related to the CHADS\textsubscript{2} score should increase in informativeness. That is, we expect that \( \lambda_{g,k}^o \) should
increase with \( g = \text{post} \), for \( k \in K_c \). We first define the two components of stroke treatment effects:
\[ \tau_{i}^{s(c)} \equiv \sum_{k \in \mathcal{K}_{i}} \tau_{i,k}^{s} \text{, and } \tau_{i}^{s(r)} \equiv \sum_{k \notin \mathcal{K}_{i}} \tau_{i,k}^{s} \] Restating Equation (11) as

\[ \tau_{i,g}^{s} = \lambda_{g}^{s(c)} \tau_{i}^{s(c)} + \lambda_{g}^{s(r)} \tau_{i}^{s(r)} + \mu_{g}^{s} + v_{i,g}^{s}, \]

we can then interpret the signal-to-noise coefficients in the equation as follows:

\[ \lambda_{g}^{s(c)} = \frac{\sum_{k \in \mathcal{K}_{i}} \sigma_{\tau(s),g,k}^{2}}{\sum_{k \notin \mathcal{K}_{i}} \sigma_{\tau(s),g,k}^{2} + \sigma_{\epsilon(s),g,k}^{2}}; \]
\[ \lambda_{g}^{s(r)} = \frac{\sum_{k \notin \mathcal{K}_{i}} \sigma_{\tau(s),g,k}^{2}}{\sum_{k \notin \mathcal{K}_{i}} \sigma_{\tau(s),g,k}^{2} + \sigma_{\epsilon(s),g,k}^{2}}. \]

If we conceptualize the posterior belief as directly formed from \( \tau_{i}^{s(c)} \equiv \tau_{i}^{s(c)} + \sum_{k \in \mathcal{K}_{i}} \epsilon_{i,g,k} \) and \( \tau_{i}^{s(r)} \equiv \tau_{i}^{s(r)} + \sum_{k \notin \mathcal{K}_{i}} \epsilon_{i,g,k} \), then we can interpret the constant, \( \mu_{g}^{s} \), and error term, \( v_{i,g}^{s} \), as

\[ \mu_{g}^{s} = \sum_{k \in \mathcal{K}_{i}} \left( 1 - \mathbf{1}(k \in \mathcal{K}_{i}) \lambda_{g}^{s(c)} - \mathbf{1}(k \notin \mathcal{K}_{i}) \lambda_{g}^{s(r)} \right) \tau_{i}^{s}; \]
\[ v_{i,g}^{s} = \sum_{k \notin \mathcal{K}_{i}} \left( \mathbf{1}(k \in \mathcal{K}_{i}) \lambda_{g}^{s(c)} + \mathbf{1}(k \notin \mathcal{K}_{i}) \lambda_{g}^{s(r)} \right) \epsilon_{i,g,k}. \]

Unlike \( \lambda_{g}^{s(c)} \) and \( \lambda_{g}^{s(r)} \), \( \mu_{g}^{s} \) and \( \text{Var} \left( v_{i,g}^{s} \right) \) are not exactly invariant to the level of aggregation with which posterior beliefs are formed.\(^{2}\) Nevertheless, regardless of this level of aggregation, qualitative interpretations are unchanged: \( \mu_{g}^{s} \) is a function of the signal-to-noise ratio and prior beliefs, and \( v_{i,g}^{s} \) is a function of signal-to-noise ratio and noise. If \( \lambda_{g,k}^{s} = 1 \) for all \( k \in \mathcal{K} \), there is no noise, and \( v_{i,g}^{s} = 0 \). At the other extreme, if \( \lambda_{g,k}^{s} = 0 \) for all \( k \in \mathcal{K} \), there is no meaningful signal. In this case, physicians will ignore all \( \tau_{i,g,k}^{s} \), and we will also have \( v_{i,g}^{s} = 0 \).

For bleeding events, we are only interested in overall treatment effects: \( \tau_{i}^{b} \equiv \sum_{k \in \mathcal{K}} \tau_{i,k}^{b} \). Restating Equation (12) as

\[ \tau_{i,g}^{b} = \lambda_{g}^{b} \tau_{i}^{b} + \mu_{g}^{b} + v_{i,g}^{b}, \]

we interpret the signal-to-noise coefficient as

\[ \lambda_{g}^{b} = \frac{\sum_{k \in \mathcal{K}} \sigma_{\tau(b),g,k}^{2}}{\sum_{k \notin \mathcal{K}} \sigma_{\tau(b),g,k}^{2} + \sigma_{\epsilon(b),g,k}^{2}}. \]

If we conceptualize the posterior belief as directly formed from \( \tau_{i}^{b} \equiv \tau_{i}^{b} + \sum_{k \in \mathcal{K}_{i}} \epsilon_{i,g,k} \), then we can similarly interpret the constant, \( \mu_{g}^{b} \), as a function of \( \lambda_{g}^{b} \) and prior beliefs, or \( \mu_{g}^{b} = \left( 1 - \lambda_{g}^{b} \right) \sum_{k \in \mathcal{K}} \tau_{i,k}^{s} \).

The error term, \( v_{i,g}^{b} \), is similarly a function of \( \lambda_{g}^{b} \) and noise, or \( v_{i,g}^{b} = \lambda_{g}^{b} \sum_{k \in \mathcal{K}} \epsilon_{i,g,k}^{s} \).

\(^{2}\)For \( \mu_{g}^{s} \) to be invariant, we require \( \lambda_{g}^{s} \) to be a different weighted average of \( \lambda_{g,k}^{s} \), with weights proportional to \( \tau_{i,k}^{s} \) rather than \( \text{Var} \left( \tau_{i,k}^{s} \right) \). For \( \text{Var} \left( v_{i,g}^{s} \right) \) to be invariant, we require \( \lambda_{g}^{s} = \text{Var} \left( \lambda_{g,k}^{s} \right) \), with weights proportional to \( \text{Var} \left( \lambda_{g,k}^{s} \right) \).
A.2 Adoption of Guideline Revealing \( (\tau^{s(c)}(x), \tau^{s(r)}(x)) \)

In this appendix, we discuss how we evaluate a counterfactual scenario in which physicians adopt a guideline that contains information on both \( \tau^{s(c)}(x) \) and \( \tau^{s(r)}(x) \). We assume that physicians who have adopted this guideline will have equal information on \( \hat{\tau}^{s(c)}(x) \) and \( \hat{\tau}^{s(r)}(x) \), which implies that \( \lambda_{\text{post}}^{s(r)} = \lambda_{\text{post}}^{s(c)} \). We assume the same distraction effects as the CHADS\(_2\) score, so that \( \alpha_{\text{post}}^{b} \) remains unchanged. To evaluate counterfactual outcomes, we need to know the effect of this policy on \( \sigma_{e,\text{post}} \).

Although this object is not identified in the data, we proceed with a bounding exercise.

We first note that adoption of the CHADS\(_2\) score did little to change \( \sigma_{e,\text{post}} \). This suggest that, although the CHADS\(_2\) score had a significant impact on physicians’ information on \( \tau^{s(c)}(x) \) (i.e., doubling \( \lambda_{\text{post}}^{s(c)} \) relative to \( \lambda_{\text{pre}}^{s(c)} \)), uncertainty about \( \tau^{s(c)}(x) \) accounts for very little in the variation in treatment decisions across patients with the same treatment effects. We therefore expect very little impact of the comprehensive guideline that also informs physicians of \( \hat{\tau}^{s(r)}(x) \).

As a baseline assumption, we consider no additional effect of the comprehensive guideline on \( \sigma_{e,\text{post}} \). We also consider a lower bound on \( \sigma_{e,\text{post}} \), which corresponds to an upper bound on the welfare improvement from the comprehensive guideline. In this lower bound, we consider the effect of the comprehensive guideline reducing the variance of \( \beta^s \lambda_{g}^{s(r)} \sum_{k \notin \mathcal{K}_c} \epsilon_{i,g,k}^s \) to 0. We note that

\[
\begin{align*}
\text{Var} \left( \beta^s \lambda_{g}^{s(r)} \sum_{k \notin \mathcal{K}_c} \epsilon_{i,g,k}^s \right) &= \left( \beta^s \lambda_{g}^{s(r)} \right)^2 \sum_{k \notin \mathcal{K}_c} \sigma_{e(s),g,k}^2 \\
&= \left( \alpha_{g}^{s(r)} / \lambda_{g}^{s(r)} \right)^2 \left( \lambda_{g}^{s(r)} \right)^2 \sum_{k \notin \mathcal{K}_c} \sigma_{e(s),g,k}^2 \\
&\leq \left( 2 \alpha_{g}^{s(r)} \right)^2 \frac{1}{4} \sum_{k \notin \mathcal{K}_c} \sigma_{\tau(s),g,k}^2 \\
&= \left( \alpha_{g}^{s(r)} \right)^2 \text{Var} \left( \tau^{s(r)}(x) \right).
\end{align*}
\]

The inequality comes from the fact that \( \left( \lambda_{g}^{s(r)} \right)^2 \sum_{k \notin \mathcal{K}_c} \sigma_{e(s),g,k}^2 \) is largest when \( \lambda_{g}^{s(r)} = \frac{1}{2} \). This occurs when \( \sum_{k \notin \mathcal{K}_c} \sigma_{e(s),g,k}^2 = \sum_{k \notin \mathcal{K}_c} \sigma_{\tau(s),g,k}^2 \). To evaluate this bound, we use the empirical variance of \( \xi_{BLP}^s(x) \approx 0.00013 \) for \( \text{Var} \left( \tau^{s(r)}(x) \right) \).

A.3 Optimal Treatment as Function of \( (\tau^s(x), \tau^b(x)) \)

In this appendix, we will examine the optimal ranking of patients as a function of \( (\tau^s(x), \tau^b(x)) \). We will use this ranking to characterize the optimal guideline under strict adherence, in which physicians follow the ranking of patients specified by the guideline. Intuitively, we find that the optimal guideline should rank patients in terms of the ratio of stroke treatment effects per bleed treatment effect. In other words, patients should be ranked by \( |\tau^s(x)|/\tau^b(x) \), and patients with the highest value of \( |\tau^s(x)|/\tau^b(x) \).
In order to see this intuition, we may first consider a social welfare function of the form

$$U_i = \bar{\beta}^s Y_i^s + \bar{\beta}^b Y_i^b,$$  
(A.8)

where $\bar{\beta}^s$ and $\bar{\beta}^b$ are social preference weights with respect to stroke and bleeds, and $Y_i^s$ and $Y_i^b$ are realize stroke and bleed outcomes. Using notation from Section 5.1, we note that $\bar{\beta}^s = W_i \beta^s (1) + (1 - W_i) Y_i^s (0)$, for $o \in \{s, b\}$. If the planner knows conditional treatment effects, $(\tau^s (x), \tau^b (x))$, defined in Equations (2) and (3) as

$$\tau^s (x) \equiv E \left[ Y_i^s (1) - Y_i^s (0) \right] \mid X_i = x;$$
$$\tau^b (x) \equiv E \left[ Y_i^b (1) - Y_i^b (0) \right] \mid X_i = x,$$

she may maximize $E [U_i]$ with the following decision rule:

$$W_i = 1 \{ \bar{\beta}^s \tau^s (X_i) + \bar{\beta}^b \tau^b (X_i) > 0 \}. \quad \text{(A.9)}$$

This decision rule is equivalent to a rule that treats if and only if $|\tau^s (x)| / \tau^b (x) > \beta^b / \bar{\beta}^s$.

Note the similarity between the decision rule implied by Equation (A.9) and our model of physician decision-making in Equation (10). Physician decisions $W_i$ will maximize $U_i$ if and only if $\bar{\beta}^s / \bar{\beta}^b = \beta^b / \beta^s$ and $f (X_i) + \nu_i = 0$ for all $i$. The first condition reflects alignment in physician preferences and social preference weights. The second condition implies that physicians perfectly observe $(\tau^s (x), \tau^b (x))$ and have no other decision-making considerations.

The decision rule in Equation (A.9) can be generalized to any arbitrary social preference ratio $\pi = \bar{\beta}^b / \bar{\beta}^s$. Suppose we consider optimal decisions under two preference ratios, $\pi$ and $\pi' < \pi$. All patients who should be treated under the preference ratio $\pi$ should also be treated under the preference ratio $\pi'$. No patients who are not treated under the preference ratio $\pi'$ should be treated under the preference ratio $\pi$. Therefore, there are only incremental patients who should be treated under $\pi'$ and not under $\pi$, and not vice versa. These patients have a ratio of treatment effects $|\tau^s (x)| / \tau^b (x) \in (\pi', \pi]$. This equivalence between patient rankings and utility maximization is noted in Vytlacil (2002) and Chan et al. (2019).

### A.4 Predicting Physician Treatment Decisions

Observable variation in treatment effects, patient age, and time trends explain a relatively small fraction of the total variation in treatment decisions. In this section, we explore other factors that might drive physician treatment decisions. Specifically, we consider the following additional variables, which may influence physicians’ treatment decisions. None of these variables are available in the AFI database, and so estimated treatment effects are not a direct function of these variables.

1. **Variables related to frailty and fall risk:** neurologic disorder (including Parkinson’s Disease), fall risk (neuropathy, muscle weakness, dizziness), vision problems, arthritis, head injury, frac-
ture. Frailty and fall risk are frequently cited clinical explanations for not prescribing warfarin to patients with high CHADS$_2$ scores. Patients with high fall risk may be more likely to suffer intracranial bleeds if they are taking warfarin.

2. *Elixhauser comorbidities that are not in the AFI database:* HIV/AIDS, deficiency anemia, hypothyroidism, tumor, metastasis, lymphoma, obesity, weight loss, paralysis, pulmonary circulation disorders, ulcer, valvular disease. These are additional patient characteristics that have been shown to predict health care spending and mortality.

3. *Variables included in the HAS-BLED score to predict bleeding risk if anticoagulated:* liver disease, renal failure, alcohol abuse, history of bleeds. These variables are included in the HAS-BLED score, which is a predictive risk score that aims to inform physicians of the risk of induced bleed, if the patient is anticoagulated. The HAS-BLED score incorporates three variables that we have already included into our predictions of bleed treatment effect heterogeneity, including age, hypertension, and stroke history; we do not consider these variables separately here, since included bleed treatment effects may already depend on these variables. The HAS-BLED also includes a measure of a measure of unstable or high INRs among treated patients, which is not observed prior to treatment, and so not included here. Finally, HAS-BLED score also includes medication usage that predisposes patients to bleeding, such as aspirin or NSAIDS. Unfortunately, we do not consistently observe the use of these medications because they are widely available over the counter, without a prescription.

4. *Variables related to patient’s ability to comply with warfarin monitoring:* drug abuse, depression, psychoses, number of years of military service. Appropriate management of patients on warfarin requires blood work repeated at regular intervals (typically every 2-4 weeks) to ensure the dosing is appropriate. Optimal dosing can depend on a patient’s diet and other medications, and may need to be adjusted from time to time as those factors change. If the warfarin dosage is too low, the patient will not reap the benefits of anticoagulation for stroke reduction; if the dosage is too high, the patient will be at elevated risk of bleeds. These variables included here are related to the likelihood that the patient can comply with the monitoring regimen.

5. *Physician characteristics:* doctor specialty code (cardiology, internal medicine, primary care). This specialty coding variable indicates the doctor’s training and role at the VHA.

Controlling for these variables in our model estimation does not materially change the conclusions of our analysis. Figure A.4 reports the results of regressions that permute the control variable sets to cover every possible combination of the above list. In Panel A, we find a similar increase in sensitivity to the CHADS$_2$-component of stroke treatment effects after guideline adoption in each model, regardless of the set of included controls. In Panel B, we show that the unexplained variance in treatment propensity does not change substantially, even after we control for these detailed patient and physician characteristics.
Figure A.1: Distribution of Physician Treatment Decisions

A. Treatment

B. CHADS\textsubscript{2} Adherence

Notes: These figures show the distribution of treatment rates and CHADS\textsubscript{2} adherence rates across physicians. They cover the subsample of 1,146 physicians treating at least 30 patients in our final analysis sample. This covers 50,426 patients treated by the higher volume doctors, or a little less than half of the VHA sample defined in Table 2. Panel A shows the distribution of treatment rates. Panel B shows the distribution of CHADS\textsubscript{2} adherence rates. We define CHADS\textsubscript{2}-adherent anticoagulation decisions as follows: No anticoagulation for patients with a CHADS\textsubscript{2} of 0 and anticoagulation for patients with a CHADS\textsubscript{2} score greater than or equal 2; we omit patients with a CHADS\textsubscript{2} score of 1 from this calculation, since the ACC and ACCP guideline allowed for either anticoagulation or aspirin for these patients.
Notes: This figure shows the probability of anticoagulation as a function of patient age in the VHA sample. The curve fits the observed data with a kernel weighted local polynomial; the shaded area represents the 95% confidence interval.
Figure A.3: Stroke Treatment Effects Among Treated Patients

Notes: This figure displays time trends in the average stroke treatment effect among treated patients, separately by CHADS£ score. The physician’s first CHADS£ mention occurs on the first day of year 0. Stroke treatment effects are predicted using causal forest rules trained and validated in the AFI database; the causal forest rules are then applied to patient characteristics in the VHA data. Adoption status and treatment decisions are measured in the VHA data.
Figure A.4: Stability of the Structural Results

A. Increase in Signal-to-Noise Ratio, $\frac{\lambda^{(c)}_{\text{pre}}}{\lambda^{(c)}_{\text{post}}}$

B. Explained Share of Latent Variable

Notes: These graphs illustrate how key results of our structural model vary as we include various sets of control variables in its estimation. Panel A examines the increase in the informativeness of physicians’ beliefs about CHADS$_2$-related stroke treatment effects with CHADS$_2$ adoption, or $\frac{\lambda^{(c)}_{\text{pre}}}{\lambda^{(c)}_{\text{post}}}$. Panel B examines the proportion of variance in the latent variable that we can explain with observable characteristics (i.e., the complement of the share explained by $\sigma^2_{e,c}$). In each panel, we include varying sets of patient characteristics in $f(X_i)$ in our structural model stated in Equation (13). We estimate the baseline specification, shown in Column 1 of Table 4. The solid line shows the mean value of the statistic among specifications with the indicated number of control sets; the top (bottom) dashed line shows the maximum (minimum) of the statistic. The control variables are detailed in Appendix Section A.4.
Figure A.5: Counterfactual Outcomes with CHA$_2$DS$_2$-VASC Guideline

A. Strict Guideline Adherence

B. Guideline Adoption (Inset)

Notes: Relative to Figure 6, this figure includes an additional set of counterfactual outcomes under strict adherence to the CHA$_2$DS$_2$-VASC guideline. Like other counterfactuals of strict adherence, strict adherence to this guideline implies ranking patients by their CHA$_2$DS$_2$-VASC score. The CHA$_2$DS$_2$-VASC score assigns one point for congestive heart failure, hypertension, age 65-74 years, female sex, vascular disease, and diabetes; it assigns two points for age 75 years or older, and for stroke, transient ischemic attack, or thromboembolism. Details for this figure are otherwise described in the notes for Figure 6.
Figure A.6: Counterfactual Outcomes, Fixed Treated Age Distribution

A. Strict Guideline Adherence

B. Guideline Adoption (Inset)

Notes: Relative to Figure 6, this figure shows counterfactual outcomes for patient rankings that hold fixed the age distribution of treated patients at every point along the curve. The fraction of treated patients in each 5-year age bin matches the fraction observed treated in our sample. Within each age group, patients are ranked according to scores in each guideline. In order to maintain a fixed age distribution of treated patients, it is not possible to treat 100% of patients. This is reflected by curves for counterfactual outcomes not reaching the same bottom-right corner of Figure 6. Only counterfactual outcomes for strict adherence and for random sorting are changed in this figure; outcomes for adoption scenarios are unchanged from Figure 6. For more details, see notes to Figure 6.
Figure A.7: Counterfactual Outcomes, Unadjusted Treatment Effects

**A. Strict Guideline Adherence**

![Graph showing counterfactual outcomes for strict guideline adherence.]

**B. Guideline Adoption (Inset)**

![Graph showing counterfactual outcomes for guideline adoption.]

*Notes:* Relative to Figure 6, this figure shows counterfactual outcomes that apply the raw stroke and bleed treatment effects from the causal forest instead of the best linear predictor (BLP) adjusted estimates. For this exercise, we bound stroke treatment effects above by 0, trimming the treatment effects for 0.06% of the sample with wrong-signed predictions of stroke treatment effects. We bound bleed treatment effects from below by 0, trimming the treatment effects for 6% of the sample with wrong-signed bleed treatment effects. While wrong-signed bleed treatment effects are more common when we do not apply the BLP adjustment, the point estimates are very close to zero, with the largest magnitude wrong-signed bleed treatment effect being $-0.003$. For more details, see notes to Figure 6.
Table A.1: AFI Database Covariates

<table>
<thead>
<tr>
<th>Variable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
</tr>
<tr>
<td>Sex</td>
</tr>
<tr>
<td>Height</td>
</tr>
<tr>
<td>Weight</td>
</tr>
<tr>
<td>Race</td>
</tr>
<tr>
<td>Smoker</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
</tr>
<tr>
<td>Diastolic blood pressure</td>
</tr>
<tr>
<td>History of angina</td>
</tr>
<tr>
<td>History of congestive heart failure</td>
</tr>
<tr>
<td>History of diabetes</td>
</tr>
<tr>
<td>History of hypertension</td>
</tr>
<tr>
<td>History of myocardial infarction</td>
</tr>
<tr>
<td>History of TIA or stroke</td>
</tr>
<tr>
<td>Worst prior event: TIA or stroke</td>
</tr>
<tr>
<td>Time from last stroke or TIA</td>
</tr>
</tbody>
</table>

Notes: This table lists all the covariates from the AFI database that are used in our causal forest implementation. We set the treatment variable to be 1 for patients treated with warfarin and 0 for patients on control or ASA therapy (aspirin). Observations are dropped for those on low warfarin and low warfarin plus ASA therapy. Patients with especially relevant disease histories missing are also excluded from the sample. These disease histories include Transient Ischemic Attack (TIA), stroke, diabetes and hypertension. We regrouped the variable “Race” so that it equals 1 when the patient is white and 0 otherwise. We constructed two binary variables related to smoking history based on the variable “Smoker” in the AFI database, which takes 3 values. The new variables, current smoker and never smoker indicates whether the patient is a current smoker and whether he or she has ever smoked. Otherwise, missing variables are replaced by their mean and mode.
Table A.2: Variable Importance

<table>
<thead>
<tr>
<th>Stroke Causal Forest</th>
<th>Stroke Regression Forest</th>
<th>Bleed Causal Forest</th>
<th>Bleed Regression Forest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke Risk (−)</td>
<td>Past Stroke or TIA (+)</td>
<td>Bleed Risk (+)</td>
<td>Age (+)</td>
</tr>
<tr>
<td>Age (−)</td>
<td>CHADS$_2$ (+)</td>
<td></td>
<td>Race (−)</td>
</tr>
<tr>
<td>Systolic Blood Pressure (−)</td>
<td>White (−)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin (+)</td>
<td>Systolic Blood Pressure (+)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Past Stroke or TIA (−)</td>
<td>Age (+)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height (+)</td>
<td>Hemoglobin (−)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHADS$_2$ (−)</td>
<td>Height (−)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White (−)</td>
<td>Past Diabetes (+)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Past Angina (−)</td>
<td>Past Angina (+)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Past Diabetes (−)</td>
<td>Past MI (+)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Past MI (−)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: Each column of this table shows the important variables for each forest in descending order of importance. Only variables selected with the LASSO procedure are included for the forests. For bleeds, LASSO only selected age and race. Risks computed from regression forest using only the control sample are then used as an input into causal forests. The +/− signs following each variable indicates the sign of its coefficient in a bivariate linear regression with the causal forest output as the dependent variable.
Table A.3: Balance Table

<table>
<thead>
<tr>
<th>Patient Characteristics</th>
<th>Control Group Mean</th>
<th>Treatment Group Mean</th>
<th>Coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>70.9</td>
<td>70.7</td>
<td>0.134</td>
</tr>
<tr>
<td>Congestive Heart Failure</td>
<td>0.27</td>
<td>0.32</td>
<td>-0.004</td>
</tr>
<tr>
<td>Age above 65</td>
<td>0.76</td>
<td>0.77</td>
<td>0.003</td>
</tr>
<tr>
<td>History of Hypertension</td>
<td>0.47</td>
<td>0.50</td>
<td>-0.007</td>
</tr>
<tr>
<td>History of Stroke</td>
<td>0.19</td>
<td>0.15</td>
<td>-0.007</td>
</tr>
<tr>
<td>History of Diabetes</td>
<td>0.15</td>
<td>0.15</td>
<td>-0.007</td>
</tr>
<tr>
<td>Male</td>
<td>0.64</td>
<td>0.66</td>
<td>-0.015</td>
</tr>
</tbody>
</table>

Notes: This table shows the unadjusted means of each patient characteristics in the treatment and control group. The last column shows results of a regression of each patient characteristics on trial fixed effects and treatment indicator in AFI database. Standard errors are shown in parentheses.
Table A.4: Causal Forest BLP Validation Regressions

<table>
<thead>
<tr>
<th>Dependent Variable</th>
<th>Stroke</th>
<th>(1)</th>
<th>(2)</th>
<th>(3)</th>
<th>Bleed</th>
<th>(1)</th>
<th>(2)</th>
<th>(3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment, $W_i$</td>
<td></td>
<td>-0.043</td>
<td>-0.041</td>
<td>0.024</td>
<td></td>
<td>(0.007)</td>
<td>(0.007)</td>
<td>(0.005)</td>
</tr>
<tr>
<td>Treatment effect interactions</td>
<td>$W_i \times \hat{r}^{o} (X_i)$</td>
<td>1.027</td>
<td>1.149</td>
<td></td>
<td></td>
<td>(0.242)</td>
<td>(0.324)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$W_i \times \hat{r}^{x(c)} (X_i)$</td>
<td></td>
<td>0.763</td>
<td></td>
<td></td>
<td>(0.340)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$W_i \times \hat{r}^{x(r)} (X_i)$</td>
<td></td>
<td>1.301</td>
<td></td>
<td></td>
<td>(0.348)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome mean</td>
<td></td>
<td>0.071</td>
<td>0.071</td>
<td>0.030</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observations</td>
<td></td>
<td>6,707</td>
<td>6,707</td>
<td>6,707</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trial fixed effects</td>
<td></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Predicted outcome controls</td>
<td>$\hat{Y}_{j,1}^{o} (X_i)$, control group</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$\hat{Y}_{j,2}^{o} (X_i)$, control and treatment groups</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: This table reports the coefficients of best linear predictor (BLP) validation regressions of stroke and bleed outcomes on treatment $W_i$ and interactions with treatment effects. Treatment effects are demeaned, so that the coefficient on the treatment indicator $W_i$ reflects the average treatment effect. All specifications control for trial fixed effects and for regression forest predictions of the outcome, $\hat{Y}_{j,1}^{o} (X_i)$, that are estimated in the control groups of leave-out trials as and analogous predictors $\hat{Y}_{j,2}^{o} (X_i)$, that are estimated in both control and treatment groups of leave-out trials. Columns 1 and 3 correspond to Equation (6), which interacts treatment with the full treatment effect, or $\hat{r}^{o} (X_i)$; Column 2 corresponds to Equation (8), which interacts treatment with the CHADS2 and the residual components of stroke treatment effects, or $\hat{r}^{x(c)} (X_i)$ and $\hat{r}^{x(r)} (X_i)$. Standard errors are shown in parentheses.
Table A.5: Patient Characteristics in the VHA Data and Across Trials

<table>
<thead>
<tr>
<th></th>
<th>VHA Data</th>
<th>AFASAK1</th>
<th>BAATAF</th>
<th>CAFA</th>
<th>SPINAF</th>
<th>SPAF2</th>
<th>AFASAK2</th>
<th>EAFT Group 1</th>
<th>PATAF Group 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>74.0</td>
<td>73.0</td>
<td>67.9</td>
<td>68.0</td>
<td>67.9</td>
<td>70.3</td>
<td>73.7</td>
<td>70.7</td>
<td>70.5</td>
</tr>
<tr>
<td>Stroke treatment effect, ( \hat{\tau}_{BLP} )</td>
<td>-0.05</td>
<td>-0.05</td>
<td>-0.03</td>
<td>-0.03</td>
<td>-0.03</td>
<td>-0.04</td>
<td>-0.04</td>
<td>-0.08</td>
<td>-0.03</td>
</tr>
<tr>
<td>Bleed treatment effect, ( \hat{\tau}_{BLP} )</td>
<td>0.03</td>
<td>0.03</td>
<td>0.02</td>
<td>0.02</td>
<td>0.02</td>
<td>0.02</td>
<td>0.03</td>
<td>0.02</td>
<td>0.02</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>0.16</td>
<td>0.52</td>
<td>0.26</td>
<td>0.22</td>
<td>0.31</td>
<td>0.21</td>
<td>0.70</td>
<td>0.09</td>
<td>0.00</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.51</td>
<td>0.32</td>
<td>0.51</td>
<td>0.39</td>
<td>0.59</td>
<td>0.53</td>
<td>0.44</td>
<td>0.44</td>
<td>0.36</td>
</tr>
<tr>
<td>Age ≥ 65</td>
<td>0.84</td>
<td>0.84</td>
<td>0.67</td>
<td>0.68</td>
<td>0.69</td>
<td>0.73</td>
<td>0.90</td>
<td>0.81</td>
<td>0.79</td>
</tr>
<tr>
<td>Diabetes</td>
<td>0.15</td>
<td>0.08</td>
<td>0.15</td>
<td>0.12</td>
<td>0.19</td>
<td>0.16</td>
<td>0.12</td>
<td>0.13</td>
<td>0.17</td>
</tr>
<tr>
<td>Stroke history</td>
<td>0.18</td>
<td>0.06</td>
<td>0.03</td>
<td>0.03</td>
<td>0.08</td>
<td>0.06</td>
<td>0.05</td>
<td>0.05</td>
<td>0.00</td>
</tr>
<tr>
<td>Male</td>
<td>0.99</td>
<td>0.54</td>
<td>0.72</td>
<td>0.75</td>
<td>1.00</td>
<td>0.70</td>
<td>0.61</td>
<td>0.59</td>
<td>0.46</td>
</tr>
<tr>
<td>Number of patients</td>
<td>113,270</td>
<td>1,007</td>
<td>420</td>
<td>378</td>
<td>571</td>
<td>1,100</td>
<td>339</td>
<td>668</td>
<td>272</td>
</tr>
</tbody>
</table>

Note: This table shows the mean of each listed patient characteristic in the VHA data, as well as each of the eight trials with both control and treatment arms in the AFI database. There are a total of 10 trials in the AFI database. In three of the trials, patients are divided into eligible versus ineligible groups for anticoagulation and then randomized within each group. In the estimation of causal forest, we treat these groups as separate trials. AFASAK1: Atrial Fibrillation, Aspirin, and Anticoagulation Study 1; BAATAF: Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA: Canadian Atrial Fibrillation Anticoagulation; SPINAF: Stroke Prevention in Non-rheumatic Atrial Fibrillation; SPAF2: Stroke Prevention in atrial Fibrillation; AFASAK2: Atrial Fibrillation, Aspirin, and Anticoagulation Study 1; EAFT Group 1: European Atrial Fibrillation Trial; PATAF Group 1: Primary Prevention of Arterial Thromboembolism in Atrial Fibrillation.
Table A.6: Probit Estimates: Additional Results

<table>
<thead>
<tr>
<th>Adoption status intercepts</th>
<th>Dependent Variable: Anticoagulant Prescription</th>
<th>(1)</th>
<th>(2)</th>
<th>(3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-adoption intercept, $\mu_{\text{post}}$</td>
<td>$-0.296^{***}$</td>
<td>$-0.274^{***}$</td>
<td>$-0.232^{***}$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(0.046)</td>
<td>(0.048)</td>
<td>(0.052)</td>
<td></td>
</tr>
<tr>
<td>Never-adopter intercept, $\mu_{\text{never}}$</td>
<td>0.015</td>
<td>0.016</td>
<td>0.023</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(0.038)</td>
<td>(0.038)</td>
<td>(0.041)</td>
<td></td>
</tr>
<tr>
<td>Standard deviation of error term</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-adoption, $\ln(\sigma_{\epsilon,\text{post}})$</td>
<td>0.015</td>
<td>0.032</td>
<td>0.115</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(0.077)</td>
<td>(0.080)</td>
<td>(0.0868)</td>
<td></td>
</tr>
<tr>
<td>Never-adopter, $\ln(\sigma_{\epsilon,\text{never}})$</td>
<td>0.012</td>
<td>0.013</td>
<td>0.0232</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(0.055)</td>
<td>(0.055)</td>
<td>(0.0576)</td>
<td></td>
</tr>
<tr>
<td>Year fixed effects, age spline controls</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Differential trends on treatment effects</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Treatment effects interacted with year identities</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Number of observations</td>
<td>113,270</td>
<td>113,270</td>
<td>113,270</td>
<td></td>
</tr>
</tbody>
</table>

Notes: This table shows additional results from the specifications reported in Table 4. The probit models allow that $\sigma_{x,e}$ may vary with adoption status (post-adoption and non-adopter) and year fixed effects. See notes for Table 4 for additional details. $^{***} p < 0.01$, $^{**} p < 0.05$, $^{*} p < 0.1$. 

A.19
Table A.7: Probit Estimates: Average Marginal Effects

<table>
<thead>
<tr>
<th>CHADS$<em>2$-related stroke treatment effect, $\hat{\tau}^{x(c)}</em>{\text{BLP}}(x)$</th>
<th>(1)</th>
<th>(2)</th>
<th>(3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-adoption, $\alpha^{x(c)}_{\text{pre}}$</td>
<td>-1.861***</td>
<td>-1.916***</td>
<td>-2.429***</td>
</tr>
<tr>
<td></td>
<td>(0.210)</td>
<td>(0.228)</td>
<td>(0.387)</td>
</tr>
<tr>
<td>Post-adoption difference, $\alpha^{x(c)}<em>{\text{post}} - \alpha^{x(c)}</em>{\text{pre}}$</td>
<td>-2.404***</td>
<td>-2.369***</td>
<td>-1.903***</td>
</tr>
<tr>
<td></td>
<td>(0.373)</td>
<td>(0.381)</td>
<td>(0.496)</td>
</tr>
<tr>
<td>Never-adopter difference, $\alpha^{x(c)}<em>{\text{never}} - \alpha^{x(c)}</em>{\text{pre}}$</td>
<td>0.372</td>
<td>0.355</td>
<td>0.440</td>
</tr>
<tr>
<td></td>
<td>(0.282)</td>
<td>(0.294)</td>
<td>(0.506)</td>
</tr>
<tr>
<td>Residual stroke treatment effect, $\hat{\tau}^{x(r)}_{\text{BLP}}(x)$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-adoption, $\alpha^{x(r)}_{\text{pre}}$</td>
<td>0.241</td>
<td>0.177</td>
<td>0.153</td>
</tr>
<tr>
<td></td>
<td>(0.121)</td>
<td>(0.128)</td>
<td>(0.698)</td>
</tr>
<tr>
<td>Post-adoption difference, $\alpha^{x(r)}<em>{\text{post}} - \alpha^{x(r)}</em>{\text{pre}}$</td>
<td>-0.366*</td>
<td>-0.305</td>
<td>-0.288</td>
</tr>
<tr>
<td></td>
<td>(0.188)</td>
<td>(0.191)</td>
<td>(0.283)</td>
</tr>
<tr>
<td>Never-adopter difference, $\alpha^{x(r)}<em>{\text{never}} - \alpha^{x(r)}</em>{\text{pre}}$</td>
<td>0.017</td>
<td>0.056</td>
<td>0.142</td>
</tr>
<tr>
<td></td>
<td>(0.160)</td>
<td>(0.165)</td>
<td>(0.347)</td>
</tr>
<tr>
<td>Bleed treatment effect, $\hat{\tau}^{b}_{\text{BLP}}(x)$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-adoption, $\alpha^{b}_{\text{pre}}$</td>
<td>-1.294***</td>
<td>-1.226***</td>
<td>-1.111**</td>
</tr>
<tr>
<td></td>
<td>(0.321)</td>
<td>(0.353)</td>
<td>(0.568)</td>
</tr>
<tr>
<td>Post-adoption difference, $\alpha^{b}<em>{\text{post}} - \alpha^{b}</em>{\text{pre}}$</td>
<td>0.974*</td>
<td>0.875</td>
<td>0.700</td>
</tr>
<tr>
<td></td>
<td>(0.517)</td>
<td>(0.541)</td>
<td>(0.695)</td>
</tr>
<tr>
<td>Never-adopter difference, $\alpha^{b}<em>{\text{never}} - \alpha^{b}</em>{\text{pre}}$</td>
<td>0.421</td>
<td>0.357</td>
<td>0.113</td>
</tr>
<tr>
<td></td>
<td>(0.416)</td>
<td>(0.436)</td>
<td>(0.739)</td>
</tr>
</tbody>
</table>

Year fixed effects, age spline controls: Yes, Yes, Yes
Differential trends on treatment effects: No, Yes, No
Treatment effects interacted with year identities: No, No, Yes
Number of observations: 113,270

Notes: This table reports average marginal effects from the specifications reported in Table 4. See notes for Table 4 for additional details. *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$. 

A.20
### Table A.8: Counterfactual Outcomes, Fixed Treated Age Distribution

<table>
<thead>
<tr>
<th></th>
<th>Treated Patients</th>
<th>Strokes Prevented</th>
<th>Bleeds Induced</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A: Benchmarks (repeated from Table 5)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Status quo</td>
<td>49.8%</td>
<td>199</td>
<td>134</td>
</tr>
<tr>
<td>Randomly assigned</td>
<td>49.8%</td>
<td>196</td>
<td>135</td>
</tr>
</tbody>
</table>

| **B: Strict Guideline Adherence, Fixed Treated Age Distribution** |  |  |  |
| Strict CHADS<sub>2</sub> adherence | 48.9% | 234 | 134 |
| Strict adherence to stroke TE guideline | 49.1% | 275 | 134 |
| Strict adherence to TE-ratio guideline | 55.6% | 287 | 134 |

*Notes:* This table reports counterfactual outcomes that hold the fixed the age distribution of treated patients. The fraction of treated patients in each 5-year age bin matches the fraction observed treated in our sample. We also hold the overall percentage of treated patients fixed at 49.8%. Within each age group, patients are treated according to rankings implied by the noted guideline. Figure A.6 shows counterfactual outcomes varying the overall percentage of treated patients. For more details, see notes to Table 5 and Figure A.6.
Table A.9: Counterfactual Outcomes, Unadjusted Treatment Effects

<table>
<thead>
<tr>
<th></th>
<th>Treated Patients</th>
<th>Strokes Prevented</th>
<th>Bleeds Induced</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A: Benchmarks</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observed treatment choices</td>
<td>49.8%</td>
<td>245</td>
<td>89</td>
</tr>
<tr>
<td>Randomly assigned treatment</td>
<td>49.8%</td>
<td>246</td>
<td>93</td>
</tr>
<tr>
<td><strong>B: Guideline Adoption</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No CHADS₂ adoption</td>
<td>49.7%</td>
<td>244</td>
<td>89</td>
</tr>
<tr>
<td>Universal CHADS₂ adoption</td>
<td>50.2%</td>
<td>252</td>
<td>91</td>
</tr>
<tr>
<td>Universal adoption of stroke TE guideline</td>
<td>49.8%</td>
<td>256</td>
<td>89</td>
</tr>
<tr>
<td><strong>C: Strict Guideline Adherence, Fixed Bleeds Induced</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strict CHADS₂ adherence</td>
<td>43.1%</td>
<td>273</td>
<td>89</td>
</tr>
<tr>
<td>Strict adherence to stroke TE guideline</td>
<td>43.4%</td>
<td>304</td>
<td>89</td>
</tr>
<tr>
<td>Strict adherence to TE-ratio guideline</td>
<td>58.5%</td>
<td>344</td>
<td>89</td>
</tr>
</tbody>
</table>

*Notes:* This table reports counterfactual outcomes that apply the raw stroke and bleed treatment effects from the causal forest rather than the best linear predictor (BLP) adjusted estimates. For this exercise, we bound stroke treatment effects above by 0, trimming the treatment effects for 0.06% of the sample with wrong-signed predictions of stroke treatment effects. We bound bleed treatment effects from below by 0, trimming the treatment effects for 6% of the sample with wrong-signed bleed treatment effects. While wrong-signed bleed treatment effects are more common when we do not apply the BLP adjustment, the point estimates are very close to zero, with the largest magnitude wrong-signed bleed treatment effect being $-0.003$. For more details, see notes to Table 5 and Figure A.7.